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Abstract 
Lyme disease is the most prevalent vector-borne disease in United States and is 
caused by the spirochete Borrelia burgdorferi. The disease is transmitted from an 
infected Ixodes scapularis tick to a mammalian host. B. burgdorferi is a highly motile 
organism and motility is provided by flagella that are enclosed by the outer membrane 
and thus are called periplasmic flagella. Chemotaxis, the cellular movement in response 
to a chemical gradient in external environments, empowers bacteria to approach and 
remain in beneficial environments or escape from noxious ones by modulating their 
swimming behaviors. Both motility and chemotaxis are reported to be crucial for 
migration of B. burgdorferi from the tick to the mammalian host, and persistent infection 
of mice. However, the knowledge of how the spirochete achieves complex swimming is 
limited. Moreover, the roles of most of the B. burgdorferi putative chemotaxis proteins 
are still elusive. B. burgdorferi contains multiple copies of chemotaxis genes (two cheA, 
three cheW, three cheY, two cheB, two cheR, cheX, and cheD), which make its 
chemotaxis system more complex than other chemotactic bacteria. In the first project of 
this dissertation, we determined the role of a putative chemotaxis gene cheD. Our 
experimental evidence indicates that CheD enhances chemotaxis CheX phosphatase 
activity, and modulated its infectivity in the mammalian hosts. Although CheD is 
important for infection in mice, it is not required for acquisition or transmission of 
spirochetes during mouse-tick-mouse infection cycle experiments. However, it has an 
effect on the survivability of spirochetes in the arthropod vectors. This is the first report 
of the role of cheD in the host tissue colonization in any pathogenic bacterium. 
Delineating the role of cheD in B. burgdorferi will provide insights into not only the 
chemotaxis pathway of this spirochete, but also its asymmetric swimming and infectious 
life cycle of the spirochete. 
Chemotaxis signal transduction systems control bacterial motility. Aside from the 
chemotaxis pathway, the architectural structure of the flagellar apparatus is also 
intimately intertwined with motility and the morphology of B. burgdorferi. Unlike other 
externally flagellated bacteria, spirochetes possess periplasmic flagella with a unique 
structural component called the collar. This unique component is located in the 
periplasmic space and is linked to the flagellar basal body. However, there are no 
reports regarding the gene(s) encoding for the collar or its function in any bacterium. In 
the second project of this dissertation, we have identified for the first time a gene, flbB, 
in any spirochete, and defined its function in motility, cell morphology, periplasmic 
flagella orientation, and assembly of other flagellar structures. We also demonstrated 
the mechanism shown as to how the organism tilts their periplasmic flagella toward the 
cell pole. 
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CHAPTER ONE: INTRODUCTION 
 Lyme disease is the most prevalent vector-borne disease in the United States 
and is caused by the spirochete Borrelia burgdorferi (1). The disease is transmitted from 
infected Ixodes ticks to mammalian hosts (2, 3). Early administration of select antibiotics 
can successfully eliminate these infections; however, similar treatment on established 
infections is less effective, and no commercial vaccine is currently available. The 
identification of novel targets for curative therapies is a significant need. 
 B. burgdorferi is a motile organism, and motility was reported to be critical for 
the infectious life cycle (tick-mouse) of the spirochete. Motility is controlled by 
chemotaxis, which allows bacteria to follow gradients of nutrients and other 
environmental stimuli. The components of the chemotaxis signal transduction systems 
that mediate these responses are highly conserved among prokaryotes. However, 
chemotaxis in B. burgdorferi is more complicated and differs from the other well-studied 
bacterial chemotaxis models such as Escherichia coli and Bacillus subtilis. The genome 
of B. burgdorferi encodes multiple homologs of several chemotaxis genes (e.g. two 
cheA, three cheW, three cheY, two cheR, and two cheB genes), making it much more 
complex than the model organisms. Most importantly, the roles of most of the B. 
burgdorferi putative chemotaxis proteins are still elusive. In this research project, we 
determined the role of a putative chemotaxis gene cheD in B. burgdorferi. The CheD 
homolog is relatively well-characterized in B. subtilis, where it plays an important role in 
chemotaxis by deamidation of methyl-accepting chemotaxis protein receptors (MCPs), 
by increasing the receptor-kinase activity or by enhancing CheC phosphatase activity, 
thereby regulating the levels of the CheY response regulator. We hypothesize that 
2 
 
CheD in B. burgdorferi would play a similar role as in other bacteria. Most importantly, 
we defined its role in mouse and tick-mouse models of Lyme disease. Delineating the 
role of CheD in B. burgdorferi will provide insights into not only the chemotaxis pathway 
of this spirochete but also its infectious life cycle. 
 B. burgdorferi has amphilophotrichous periplasmic flagella. The periplasmic 
flagella form a ribbon-like structure that wrap around the cell body or cylinder. When 
empowered by the motor rotation, the periplasmic flagella are rotated symmetrically or 
asymmetrically, resulting in complicated swimming behaviors (run, reverse or flexing 
swimming modes). The chemotaxis signal transduction system controls the rotation of 
flagella (see details below). Beside from the chemotaxis molecules, the flagellar motor 
components are also closely intertwined with the motility in this spirochete. Unlike other 
externally flagellated bacteria, the spirochetes periplasmic flagella contain a unique 
structure called the collar. However, nothing was known about the genes encoding the 
collar structure or their function in any spirochete. This novel component is conserved 
among spirochetes and located in the periplasmic space. Most interestingly, the collar is 
seen directly connected with the major component of the flagella leading to the 
hypothesis that the collar is important for flagellar assembly or providing proper rigidity 
and flexibility of flagella within the periplasmic space during rotation. In this research 
project, we identified and characterized a gene, flbB, that was found to be involved in 
the assembly of the collar structure. Understanding the intimate relationship between 
bacterial motility and the spirochetal unique collar structure in B. burgdorferi can provide 
ideas to comprehend an enigmatic spirochetes’ asynchronous motility. In addition, this 
spirochete conserved collar structure could be a target for the new drug to disrupt 
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flagellar assembly. The structural information of the collar has provided new 
opprotunities for structure-based drug design, which would block motility and the spread 
of Lyme disease as well as other spirochete-borne diseases in the future. 
LYME DISEASE 
History and discovery of Lyme disease. Lyme disease was first recognized in 
the 1970s. In 1975, a tight geographic clustering of children in the area of Old Lyme, 
Connecticut displayed a mysterious syndrome which was initially thought to be juvenile 
rheumatoid arthritis. Dr. Allen Steere, a rheumatology resident at Yale University, 
investigated 51 residents who developed symptoms characterized by recurrent attacks 
of asymmetric swelling and pain in a few large joints, especially the knee, and 
suggested that this clinical manifestation was transmitted by an arthropod vector, and 
described it as Lyme arthritis in 1977 (4). He contacted Dr. Willy Burgdorfer, a medical 
entomologist at Rocky Mountain Laboratories of National Institute of Allergy and 
Infectious Diseases (NIAID), to investigate the Lyme arthritis. In 1982, Dr. Burgdorfer 
discovered a spirochete in the midgut of an Ixodes scapularis tick (5). The following 
year, he investigated the connection between this spirochete and Lyme disease (6), and 
in honor of its discoverer, the organism was named after him “Borrelia burgdorferi” (7). 
Even though the first recognized case of Lyme disease was reported only 40 years ago, 
the oldest human case of infection with B. burgdorferi was discovered by whole-genome 
sequencing in the Tyrolean Iceman which is a 5,300-year-old Copper Age individual, 
discovered in 1991 on the Tisenjoch Pass in the Italian part of the Ö tztal Alps (8). In 
2014, Dr. George Poinar Jr. in Oregon State University found spirochete-like cells 
(Spirochaetales: Spirochaetaceae) in the hemocoel and lumen of the alimentary tract of 
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a larva tick (Amblyomma sp. Arachnida: Ixodidae) which has similar size and shape of 
the present-day Borrelia species in 20-15 million year old Dominican amber fossil (9). 
This discovery of fossil spirochetes established a minimum time period of 20-15 million 
years when hard ticks were infected with Borrelia-type spirochetes. 
Clinical manifestations of Lyme disease. The initial classification of Lyme 
disease was uncomplicated: erythema migrans (stage 1), meningitis or Bell’s palsy 
(stage 2), and arthritis (stage 3) (10). However, the disease was re-classified in a 
system similar to that used to classify syphilis (11) due to the overlap of the clinical 
manifestations at different stages. Lyme disease is now subdivided into three different 
stages based on infection time (12-14). 
Stage 1, early localized Lyme disease, occurs 3 to 30 days after an infected tick 
bite. The most common and clinical hallmark of this stage of Lyme disease is a skin 
rash known as erythema migrans (Fig. 1.1.A). This skin rash occurs in approximately 70 
to 80 percent of patients, and typically appears at the site of the tick bite after a delay of 
about one week (ranging from 3 to 32 days), as a small red erythematous macule or 
papule due to the peripheral lymphocytic and eosinophilic infiltration of cutaneous 
vessels (3, 14, 15). The lesion subsequently enlarges, and may have vesicles or 
necrotic areas at the center. This lesion tends to have red outer borders with partial 
central clearing that can reach 61 cm (2 ft) in diameter or larger, for that reason the rash 
is also known as a “bull’s-eye rash” (16-19). Erythema migrans lesions are able to occur 
anywhere on the body surface, although common sites are the back, legs, waist, groin, 
axilla, and in children the head and neck. The lesion itself is usually asymptomatic but 


























Figure 1.1. Signs and symptoms of untreated Lyme disease. From Lyme 
disease, Centers for Disease Control and Prevention. Available at: 
http://www.cdc.gov/lyme/signs_symptoms/index.html. Accessed August 17, 2015. 
(A) “Classic” erythema migrans rash. (B) Facial palsy. (C) Lyme arthritis. 
(A) (B) (C) 
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such as fatigue, headache, cough, arthralgia, myalgia, stiff-neck, regional 
lymphadenopathy, and, less often, low-grade fever (10, 16-19). 
Most patients with erythema migrans (70 to 80% of all patients) have a single 
lesion, but the bacteria are able to migrate out hematogeneously to other sites in the 
skin and to the extracutaneous sites. This disseminated infection is classified as stage 
2, early-disseminated Lyme disease, and occurs in 2 to 8 weeks after the tick bite. The 
most common clinical manifestation of this stage is multiple erythema migrans. These 
secondary lesions appear 3 to 5 weeks after the tick bite and consist of multiple annular 
erythematous lesions similar to, but usually smaller than the primary lesion (3, 19). 
Extracutaneous manifestations of this stage of Lyme disease include neurologic 
conditions, such as cranial-nerve palsy (particularly facial-nerve palsy, also known as 
Bell’s palsy) (Fig. 1.1.B), and meningitis that mimics aseptic meningitis. Neurological 
manifestations, such as peripheral and central nervous dysfunction, occur due to the 
lymphocytic infiltration (15). Rarely, carditis, which is most commonly manifested by 
various degrees of atrio-ventricular (A-V) blockage, may also occur at this stage (3, 20-
22). 
Stage 3, late persistent Lyme disease, occurs in 6 months after the tick bite. In 
the United States, the most common sign of late Lyme disease is arthritis, and it occurs 
in approximate 31% of all Lyme disease cases, and in less than 10% of all cases where 
patients were treated. Arthritis occurs weeks to months after the initial infection; it is 
usually monoarticular or oligoarticular (4, 23) and affects the large joints, particularly the 
knee (Fig. 1.1.C). Arthritis is believed to be not dependent on immune complex 
deposition, but rather a dysregulated cytokine and cell-mediated response. It is unclear 
7 
 
whether pathology is due solely to recognition of Borrelia spirochetes within the joint, or 
whether molecular mimicry is underlying an autoimmune based mechanism (15). Even 
though the joints are swollen and tender, the intense pain associated with septic arthritis 
is usually not present. Approximately 10% of patients are refractory to antimicrobial 
treatment at this stage of Lyme disease (24, 25). 
The various clinical manifestations of chronic Lyme disease have been 
associated with different tissue tropisms of the three genospecies of Borrelia. In the 
United States, 31% of Lyme disease cases reported through national surveillance are 
associated with arthritis which is caused by a B. burgdorferi sensu stricto infection, 
whereas only 12% have neurologic symptoms (usually facial palsy) (26). Carditis is 
universally rare, generally accounting for less than 1% in most series (1, 27). 
Neurological and cutaneous manifestations such as neuroborreliosis and chronical skin 
rash (acrodermatitis chronica atrophicans) are often associated with B. afzelii and B. 
garinii infections, respectively (28, 29). These dermatologic and neurologic 
manifestations of Lyme disease are well known in Europe but are extremely rare in the 
United States (30). 
Infection rate and mortality of Lyme disease. The cases of Lyme disease 
reported by the Centers for Disease Control and Prevention (CDC) increased 
approximately 260% between 1997 (12,801 cases) and 2014 (33,461 cases). Each 
year, approximately 30,000 cases of Lyme disease are reported, and the total cost of 
Lyme disease now tops two billion dollars annually in the United States (31-33). 
However, the CDC reported by its own investigation that the actual number of Lyme 
disease cases is underreported due to the lack of distinct disease symptoms and simple 
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diagnostic assays. The CDC estimates the actual cases of Lyme disease in the United 
States is approximately 300,000 each year with medical costs estimates over twenty 
billion dollars each year (34). Based on this report, the infection rate of Lyme disease in 
United States is ≥ 100 cases per 100,000 in the population, which is similar to the scale 
seen with gonorrhea—the second most-commonly reported infectious disease in United 
States (350,062 cases in 2014, 110.7 cases per 100,000 population) (35). 
Although Lyme disease shows high infection rate, mortality rate of Lyme disease 
is very low. Based on systematic analysis of the medical literature, only a few cases of 
death caused by Lyme disease have been reported worldwide (36-42). From 1999 to 
2003, 23 cases of death by Lyme disease were reported; however, 11 cases were 
improperly coded, and only one listed a consistent causal sequence (43). The potential 
for occult death caused by Lyme carditis was verified by a recent report of fatal Lyme 
carditis cases investigated through postmortem examination of donated tissues (44). 
Nonetheless, a follow-up study of more than 120,000 patients with Lyme disease during 
1995 to 2013 found that only 0.6% died of any causes within a year of diagnosis, a rate 
less than the expected, age-adjusted, all-cause mortality for this population (27). 
Diagnosis and treatment of Lyme disease. The CDC proposed that Lyme 
disease is diagnosed based on signs, symptoms, and a history of potential exposure to 
ticks in an area where Lyme disease is endemic (45). The clinical diagnosis of Lyme 
disease can be straightforward in patients with a history of infected tick exposure and 
physical findings (e.g., erythema migrans rash) (46). Although the erythema migrans 
rash is a distinctive sign for diagnosis of Lyme disease, a number of conditions 
resemble erythema migrans (Table 1.1) (47, 48); however, the rapid and prolonged  
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Erythematous macule or papule at site of tick bite (although the 
tick is often not seen); enlarges relatively rapidly to 5–30 cm or 
more in diameter; typically flat and annular; usually uniformly 
erythematous or with heightened central erythema; may have 
central clearing; without treatment, persists for average of 3–4 
weeks* 
Cellulitis 
Homogenous erythematous lesions associated with edema, 
tenderness, and warmth; enlarges rapidly; rarely circular; most 
commonly adjacent to an ulcer, laceration, or wound 
Granuloma annulare 
Small (2–5 cm in diameter), scaling erythematous lesions with 
central clearing; most commonly located on the feet and 
hands; develops over weeks; often on dorsum of extremities 
Hypersensitivity 
reaction/dermatitis 
Lesions of variable shape and size that may resemble certain 




Erythematous lesions of variable size that may be associated 
with necrotic eschar; most commonly located on the 
extremities, but may involve the axilla, abdomen, chest, or 
back 
Nummular eczema 
Coin-shaped erythematous lesions that range in size from 2–
10 cm; does not enlarge rapidly; pruritic; well demarcated; skin 
may be thickened or weepy; Most commonly located on the 
back and hands 
Spider bite 
Erythematous lesions of variable size that may be associated 
with necrotic eschar; often very painful; most commonly 
located on the extremities 
Insect bite 
Often raised papule with central punctum; pruritic; usually 
smaller than erythema migrans lesion; rarely continues to 
enlarge 
Tinea (ringworm) 
Annular or ring-form lesions of variable size with central 








Multiple ring like lesions; typically do not enlarge rapidly; a 




Symmetric lesions (most are less than 2 cm in diameter) with 
central clearing; cause may be apparent (e.g., drug or 
infection); diffuse lesions with mucous membrane involvement 
Urticaria 
Raised erythematous lesions with an associated serpiginous 
border; may appear and disappear rapidly; variable region 
*A similar lesion is found in southern tick-associated rash illness (STARI), which occurs 
primarily in southeastern and south central states. STARI does not have extracutaneous 














expansion of an erythematous lesion is unique to erythema migrans (16). Lesions most 
often occur at anatomic sites that are unusual for cellulitis and other conditions that 
mimic erythema migrans (e.g., back, groin, abdomen, axilla, popliteal fossa). Therefore, 
a complete skin examination should be performed before excluding erythema migrans 
(21). 
Validated laboratory tests are generally of little use in patients with erythema 
migrans (48). The CDC and Infectious Diseases Society of America (IDSA) 
recommended serological tests as the most preferred initial diagnostic laboratory test 
(21, 50). Currently, the CDC recommends two-tier serology tests when analyzing blood 
for evidence of B. burgdorferi-specific antibodies in the patients with suspected Lyme 
disease. The first step uses a sensitive method such as enzyme linked immunosorbent 
assay (ELISA) or immunofluorescence assay (IFA). These tests should detect both 
immunoglobulin M (IgM) and IgG antibodies against B. burgdorferi. If the first-tier 
samples are positive or equivocal, a second step should be performed to confirm the 
results. The second step uses Western blot analysis, which detects separate IgM and 
IgG antibodies against borrelial specific antigens. The following criteria for a positive 
Western blot are adapted from the CDC; IgM should be reactive against 2 or 3 of 3 
antigens [p21 (OspC), p39 (BmpA), and p41 (FlaB)], and IgG should be reactive against 
5 or more of 10 antigens [p18, p21 (OspC), p28, p30, p39 (BmpA), p41 (FlaB), p45, 
p58, p66, and p93].  (50-53). Even though the two-tier test is used as a standardized 
method for Lyme disease diagnosis, it has low sensitivity in early infection, but is highly 
sensitive after 6 to 8 weeks of untreated infection (54). 
In synovial fluid samples from patients with untreated late Lyme arthritis,  
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polymerase chain reaction (PCR) analysis has shown the highest sensitivity (47, 55, 
56). However, borrelial DNA may persist after spirochetal killing, which limits its use as 
a test for active infection. Therefore, IDSA recommended that PCR testing be used as 
an optional test to further support the diagnosis for selected patients with late Lyme 
arthritis or neurological Lyme disease (21, 23). The urine borrelial antigen test is not 
recommended due to a high false-positive rate (57, 58). 
Lyme disease usually can be treated with antibiotics. Lyme disease have various 
stages, and treatments differ according to the stage of infection. Both oral and 
intravenous (IV) antibiotics therapies are typically used in Lyme disease patients. The 
IDSA provided guidelines for the treatment of Lyme disease (Table 1.2) (21, 47, 54). 
Oral antibiotics administration (e.g. doxycycline, amoxicillin, or cefuroxime axetil for 14 
days) is the recommended treatment for early localized or disseminated Lyme disease, 
in the absence of specific neurologic manifestations. Patients of Lyme disease with 
neurological manifestations are usually treated with IV antibiotics therapies. For 
instance, the IV antibiotic therapy (e.g. ceftriaxone for 14 days) is recommended for 
early Lyme disease adult patients with acute neurological manifestation such as 
meningitis or nerve root disorder (radiculopathy) (21). Patients of Lyme disease with 
cardiac symptoms, or, in a few cases, refractory Lyme arthritis are also treated with the 
IV regimens. Treatment of Lyme arthritis patients is more complex. Lyme arthritis 
patients are initially treated with an oral antimicrobials administration (e.g. doxycycline, 
amoxicillin, or cefuroxime axetil for 28 days). During and after the oral antibiotic therapy, 
non-steroidal anti-inflammatory drugs are commonly used to ameliorate symptoms. 
Lyme arthritis patients with neurological symptoms should receive IV ceftriaxone 
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Table 1.2. Preferred antimicrobial therapies for Lyme disease* 







100 mg orally twice a 
day 
 
<8 years: not 
recommended; ≥8 
years: 4 mg/kg/day in 
2 divided doses 
(maximum 100 
mg/dose) 
14 days (10–21 
days) 
 Amoxicillin 
500 mg orally 3 times 
a day 




14 days (14–21 
days) 
 Cefuroxime axetil 
500 mg orally twice a 
day 









    
Cranial nerve palsy# 
Same as for erythema 
migrans 
Same as for erythema 
migrans 
Same as for erythema 
migrans 




Ceftriaxone 2 gm IV per day 
50–75 mg/kg IV per 
day in a single dose 
(maximum 2 gm/day) 
14 days (10–28 
days) 
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Table 1.2. Preferred antimicrobial therapies for Lyme disease* (~continue) 




Same as oral regimen 
for erythema migrans 
or use IV regimen as 
for neurologic 
disease† 
2 gm IV per day 
50–75 mg/kg IV per 
day in a single dose 
(maximum 2 gm/day) 
14 days (14–21 
days) 




Same as for erythema 
migrans 
Same as for erythema 
migrans 
Same as for erythema 
migrans 
28 days (28 days) 
Recurrent arthritis 
after oral regimen 
Repeat oral regimen 
or use IV regimen as 
for neurologic disease 
Repeat oral regimen 
or use IV regimen as 
for neurologic disease 
Repeat oral regimen 
or use IV regimen as 
for neurologic disease 
28 days for oral 
regimens, 14–28 
days for IV regimens 
Central or peripheral 
nervous system 
disease 
IV regimen as for early 
neurologic disease 
IV regimen as for early 
neurologic disease 
IV regimen as for early 
neurologic disease 
14 days (14–28 
days) 
*Complete response to treatment may be delayed beyond the treatment period, regardless of the clinical manifestation, 
and relapse may recur. Patients with objective signs of relapse may need a second course of treatment. For a complete 
list of recommended and alternate therapies (21). 
 




#Patients without clinical evidence of meningitis may be treated with an oral regimen. The recommendation is based on 
experience with seventh cranial nerve palsy. Whether oral therapy would be as effective for patients with other cranial 
neuropathies is unknown; the decision between oral and parenteral therapy should be individualized. 
 
##For nonpregnant adult patients who are intolerant of β-lactam agents, doxycycline 200–400 mg/day orally [or 
intravenously (IV) if unable to take oral medications] in 2 divided doses may be adequate. For children ≥8 years of age, 
the dosage of doxycycline for this indication is 4–8 mg/kg/day in 2 divided doses (maximum 200–400 mg/day). 
 
†A parenteral antibiotic regimen is recommended at the start of therapy for patients who have been hospitalized for 
cardiac monitoring; an oral regimen may be substituted to complete a course of therapy or to treat outpatients. A 
temporary pacemaker may be required for patients with advanced heart block. 
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treatment. If incomplete resolution of arthritis is observed with the patients after 4 weeks 
oral treatment, an additional course of oral or IV antibiotics treatment may be necessary 
(21). 
About 10% of patients with Lyme arthritis develop antibiotic-refractory Lyme 
arthritis (or treatment-resistant Lyme arthritis) in the United States, and this joint 
inflammation persists for months to several years after antibiotic therapy (59). B. 
burgdorferi DNA is undetectable by PCR in synovial fluid from these chronic Lyme 
arthritis patients, but is detectable before antibiotic therapy. This suggests that 
antibiotic-refractory Lyme arthritis is not caused by chronic spirochete infection (60). 
Instead of a chronic infection, investigators suggest a link between the development of 
antibiotic-refractory Lyme arthritis and induction of autoimmunity. 
The histologic lesion of this antibiotic-refractory Lyme arthritis mimics that of 
rheumatoid arthritis. Synovial tissue samples reveal hypertrophy, neovascularity, 
macrophage infiltration, and a mixed population of lymphocytes typically found in 
subsynovial areas (61). The majority of patients with antibiotic-refractory Lyme arthritis 
have human lymphocyte antigen (HLA)-DRB1*0401 or related alleles (62, 63), which 
are associated with the severity of rheumatoid arthritis (64). Moreover, the severity and 
duration of antibiotic-refractory Lyme arthritis correlates with cellular and humoral 
immune responses to outer surface protein A (OspA) of the spirochete. The OspA165–173 
epitope region has been shown to have sequence homology with human lymphocyte 
function associated antigen-1 (hLFA-1), and it has been predicted to bind to the 
DRB1*0401 molecule (61). In most antibiotic-refractory patients with Lyme arthritis, their 
T cells from synovial fluid responded to both OspA and hLFA-1, whereas those from 
17 
 
patients with other forms of chronic inflammatory arthritis did not (61). Although the 
pathogenesis of this antibiotic-refractory Lyme arthritis is still unclear, increasing the 
frequency of certain class II major histocompatibility complex (MHCII) molecules such 
as HLA-DR3 and HLA-DR4 alleles (61, 63), and molecular mimicry between a dominant 
T cell epitope of OspA and hLFA-1 (60, 61) may be an important factor in the 
persistence of joint inflammation in genetically susceptible patients with antibiotic-
refractory Lyme arthritis. 
Vaccine against Lyme disease. Although antibiotics therapies are effective 
treatment for Lyme disease, approximately 10% of patients still suffer from post-
treatment Lyme disease syndromes such as treatment-resistant Lyme arthritis (65-67). 
In addition, the emergence rate of drug-resistant bacteria has been increasing in recent 
decades and cause serious problems not only in B. bugdorferi but also in other 
infectious bacteria (68-70). Based on pharmaco-economic studies, almost two billion 
dollars spent on medical claims for Lyme disease in the United States every year (32, 
33). To prevent antibiotic overuse and reduce medical claims for Lyme disease, 
vaccines for Lyme disease are clearly needed (71, 72). 
Currently, several licensed veterinary vaccines are available in the market; 
however, human Lyme disease vaccines are not commercially available at present (73). 
Previously, two pharmaceutical companies developed vaccines for Lyme disease in the 
early 1990s for human use. The US Food and Drug Administration (FDA) previously 
licensed a vaccine for Lyme disease on December 21, 1998, which was registered as 
LYMErix by SmithKline Beecham (now called GlaxoSmithKline). Another vaccine was 
registered as ImuLyme by PasteurMe ŕieux-Connaught. However, the company did not 
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go forward with a biologic license application for the vaccine, despite efficacy in their 
phase III clinical trial (74-77). Both vaccines were designed against the B. burgdorferi 
outer surface protein A (OspA). The vaccine inoculator developed circulating 
bactericidal antibodies against the OspA that would be ingested by the tick during a 
blood meal. These antibodies would then be sufficient to bind and neutralize viable B. 
burgdorferi present in the tick gut, such that, during a blood meal, infectious spirochetes 
could not be regurgitated through the dermis, effectively preventing infection. However, 
the tenure of LYMErix was short, purportedly due to poor sales. In the 2001, sales of 
LYMERix had decreased to five million dollars annually with the purchase of only 
93,000 doses of vaccine. In the first 2 months of 2002, sales had dwindled to 10,000 
doses (78). Due to the low public demand for the vaccine, the manufacturer voluntarily 
withdrew the vaccine production and marketing of LYMERix in February 2002. The 
decline in sales could be traced to concerns, real or perceived, of possible adverse 
effects, including a chronic inflammatory arthritis that could theoretically develop in HLA-
DR4 positive patients (i.e. vaccine associated auto-immune arthritis) (79). The outer 
surface protein A, OspA-based vaccines have another concern that is the frequency of 
boosts required to maintain long-term protection. B. burgdorferi upregulated the 
expression level of OspA in the larval tick host after first blood meal. OspA is expressed 
in the tick midgut to tether with a tick midgut protein TROSPA (80). After larvae molted 
into the nymphs, the nymphal ticks feeding on a mammalian host. During this second 
blood meals, B. burgdorferi OspA is rapidly downregulated, resulting in spirochetes no 
longer being tethered to the tick midgut and migrating out to salivary gland and 
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subsequently to the dermis of the host. In the mammalian host, OspA is poorly 
expressed (81, 82). 
These problems associated with OspA-based vaccines can be avoided by using 
different antigens, which are expressed at high levels during mammalian infection, such 
as outer surface protein C, OspC (83). OspC is immunodominant during early infection 
in the mammalian host and can elicit bactericidal antibodies, however, the protective 
range is narrow (84, 85). Because OspC is one of the most highly diverse proteins of B. 
burgdorferi; OspC sequences form at least 38 distinct phyletic ospC clusters or types 
(86-88), and its inherent diversity has hampered OspC vaccine development. 
Identification of protective epitopes of each OspC type will allow for construction of 
recombinant, polyvalent, chimeric vaccines that will elicit broad protection. Thus, a 
tetravalent and an octavalent vaccine based on OspC types have been developed. 
These constructs elicited an antibody response against each of the components 
epitopes, and those antibodies show a complement-dependent bactericidal activity (89, 
90). A DNA-vaccine encoding an ospC gene was also shown to be suitable for inducing 
protection against Lyme borreliosis (91). However, a limited number of studies for Lyme 
disease vaccine are being investigated since 2002, and there has been no active, 
sustained interest in developing or licensing a new Lyme disease vaccine in the United 
States. 
Epidemiology of Lyme disease. According to the CDC, Lyme disease has been 
the most common vector-borne disease in United States since 1985 (26), and has been 
a nationally notifiable condition since 1991 (1). In 2014, Lyme disease was the fifth most 
common nationally notifiable disease. From 1992 to 2014, the United States and its 
20 
 
territories reported 455,899 confirmed cases of Lyme disease to the CDC (26, 35, 92-
94). During this period, annual case counts continuously increased approximate 3-fold, 
from 9,908 cases in 1992 to 33,459 cases in 2014 (Fig. 1.2) (26, 35, 92-94). Within 
North America, the incidence of Lyme disease is highest in the Northeastern, Mid-
Atlantic, and North Central United States. In 2014, more than 96% of confirmed Lyme 
disease cases in the United States were reported from 14 states; Connecticut, 
Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, 
New York, Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin (Fig. 1.3.A). 
The genus Ixodes ticks are well-known vectors for transmitting Lyme disease. In the 
Eastern and North Central United States, the Ixodes scapularis tick (also known as the 
black-legged tick) is the main vector (infection rate >50%) (Fig. 1.3.B), whereas in the 
Pacific States transmission occurred mainly by the I. pacificus (also known as the 
Western black-legged tick, infection rate 1-6%) (Fig. 1.3.C). The white-footed mouse 
(Peromyscus leucopus) is the primary reservoir of B. burgdorferi in the Northeastern 
United States (95). Mice are generally infected when fed upon by primarily nymphal 
stage Ixodes ticks, which acquired B. burgdorferi during the larvae stage blood feeding 
on small mammalian hosts (96). The white-tailed deer (Odocoileus virginianus) serves 
as the primary host for adult ticks.  
Interestingly, lizards rarely serve as competent reservoir hosts in the United 
States. The western fence lizard (Sceloporus occidentalis) is naturally and 
experimentally refractory to B. burgdorferi infection. The alternative complement 
pathway of S. occidentalis typically destroys B. burgdorferi present in the tissues of 


























Figure 1.2. Number of reported Lyme disease cases, United States, 1995 to 
2014. From Lyme disease, Centers for Disease Control and Prevention. Available at: 
http://www.cdc.gov/lyme/stats/graphs.html. Accessed November 5, 2015. 
*




Figure 1.3. Geographic distribution of confirmed Lyme disease cases, United 
States in 2014 (A), Ixodes scapularis (Blacklegged tick) (B), and Ixodes 
pacificus (Western blacklagged tick) (C). (A) From Lyme disease, Centers for 
Disease Control and Prevention. Available at: 
http://www.cdc.gov/lyme/stats/maps.html. Accessed November 5, 2015. (B, C) From 
Geographic distribution of ticks that bite humans, Centers for Disease Control and 
Prevention. Available at: http://www.cdc.gov/ticks/geographic_distribution.html. 





transmission of spirochetes to humans and other animals by the resulting adult ticks 
(97, 98). Based on this consequence, ecologists have proposed the hypothesis that the 
reason for lower Lyme disease incidence in California and the Southern part of United 
States is based on the population of lizards between epidemic and non-epidemic region 
of Lyme disease (99-101). 
Infectious life cycle (Mammalian and Ixodes tick hosts). Ixodes ticks undergo 
a four-stage life cycle: the egg, larva, nymph, and adult stages (Fig. 1.4). The larvae are 
uninfected when they are hatched from eggs. These naïve larvae can acquire the 
spirochetes from an infected small-mammal or avian reservoir hosts during their first 
blood meal. After molt into nymphal stage, the nymphs transmit the spirochetes (if 
acquired during the larval stage) into the mammalian host during the tick’s second blood 
meal. The number of B. burgdorferi transmitted varies from 10 to 10,000, with an 
average of approximately 1,500 (102). Fed nymphs molt into adult ticks, and the adults 
feed predominantly on larger vertebrate hosts such as a white tailed deer (O. 
virginianus). Although deer are incompetent hosts for persistence of B. burgdorferi, they 
are important for maintenance of the tick population because adult ticks mate on this 
large mammalian host. After mating, the male tick dies and the female lays eggs on the 
forest floor before dying (1, 2). 
Transovarial (eg. mother-to-egg) transmission of B. burgdorferi in Ixodes ticks 
has been reported to possibly occur in 1–5% of ticks (103-105). However, the number of 
transovarially infected ticks are rare and inadequate to maintain the infected populations 
of either the tick vector or vertebrate hosts (106). In addition, recent experimental 














Figure 1.4. The enzootic life cycle of B. burgdorferi. Ixodes scapularis (also 
known as the blacklegged tick) is the main vector of B. burgdorferi in the United 
States, and has a two-year life cycle with four life stages: the eggs, and three 




therefore, are most likely born uninfected. 
Until now, Lyme disease is believed to be only transmitted by the bite of infected 
arthropod vectors. Recently, few intriguing studies have suggested the clinical, 
epidemiological, and experimental evidence for sexual transmission of Lyme disease in 
animal models (108-111) and humans (112-115). This hypothesis of sexual 
transmission of the B. burgdorferi remains speculative, it might create a paradigm shift 
that would transform Lyme disease from a tick-borne illness into a sexually transmitted 
infection (116). 
There is no cases of Lyme disease have been reported by blood transfusion 
(117, 118). However, investigators have found that Borrelia species can live in blood 
that is stored for donation (119, 120). For that reason, CDC and Red Cross restricted 
the blood donation from individuals being treated for Lyme disease with an antibiotic. 
BORRELIA BURGDORFERI 
 Taxonomy of B. burgdorferi. Spirochetes are a group of phylogenetically-
distinct eubacteria (121). The phylum Spirochetes is composed of a single class 
(Spirochetes) and order (Spirochetales). The order is divided into three families: 
Brachyspiraceae, Leptospiraceae, Spirochaetaceae (122). Within the family 
Spirochaetaceae is the genus Borrelia. Of the 37 known Borrelia species, 12 can cause 
Lyme disease (123) (Fig. 1.5). Since the discovery of B. burgdorferi in 1982, 10 different 
tick-borne Borrelia species have been identified; B. burgdorferi sensu stricto (124), B. 
garinii (124), B. afzelii (124, 125), B. japonica (126), B. valaisiana (127), B. lusitaniae 
(128), B. andersonii (129), B. tanukii (130), B. turdi (130) [the name has been corrected 


























Figure 1.5. Phylogeny of Spirochetes. Members of the phylum Spirochaetes are 
easily identified by their unique coiled morphology and periplasmic flagella. The 
phylum is composed of a single class (Spirochaetes) and order (Spirochaetales), 











Figure 1.6. Phylogeny of Lyme disease spirochete isolates as inferred from 
16S rRNA gene sequence analysis. The phylogenetic tree was constructed by 
using the neighbor-joining method in the MEGA program. A total of 28 B. burgdorferi 
sensu lato isolates representing 10 different Borrelia species were included in this 
analysis. B. hermsii HS1 was used as the outgroup. Numbers at the branch nodes 




burgdorferi sensu lato” is collectively used for all Borrelia isolates within this cluster and 
to distinguish it from the species “Borrelia burgdorferi sensu stricto” (strict sense of 
Borrelia burgdorferi) (124). 
 Biology of B. burgdorferi. Spirochetes, including B. burgdorferi, have unique 
and distinctive structural features: 1) helical or flat-wave morphology and four swimming 
modes; 2) a double-membrane: an outer membrane without the lipopolysaccharide 
(LPS) and phosphatidylethanolamine that surrounds the protoplasmic cylinder complex, 
consisting of the cytoplasm, the peptidoglycan complex, and the inner membrane; and 
3) periplasmic flagella instead of external flagella seen in most motile bacteria. 
Spirochetes flagellar filaments are located in the periplasmic space between the outer 
membrane and the peptidoglycan layer with the flagellar basal body embedded in the 
inner membrane (Fig. 1.7) (134-136). B. burgdorferi is a long and thin bacterium, 10–20 
μm in length and 0.33 μm in diameter (137). The shape of this spirochete is 
characterized as a planar, regular, with periodic undulation of the cell body of an 
amplitude of 0.78 μm and a wavelength of 2.83 μm (called the flat-wave morphology) 
(138). B. burgdorferi is a fastidious bacterium, which means it requires a rich growth 
medium. These bacteria can be cultured in vitro with Barbour-Stoenner-Kelly (BSK) II 
medium, which constitutes CMRL-1066 without L-glutamine, neopeptone, yeastolate, 4-
(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), glucose, sodium citrate, 
sodium pyruvate, sodium bicarbonate, N-acetylglucosamin, bovin serum albumin, and 
rabbit serum (139), at 30–37°C in microaerophilic conditions (5, 140, 141). Even under 
optimal laboratory conditions, the generation time for B. burgdorferi is long, dividing 


























Figure 1.7. Dark-field microscopic image, and schematic diagram of B. 
burgdorferi. (A) Wild-type B. burgdorferi possesses a distinctive flat-wave 
morphology (left), while B. burgdorferi ΔflaB mutant cell form a straight rod shape 
(right). One enlarged cell from microscopic field is shown in yellow. (B) Longitudinal 
diagram (top) and cross-section diagram (bottom) of B. burgdorferi. Note that 
periplasmic flagella overlap in the cell center, and form a tightly packed ribbon that 











cell densities of about 108/ml (141-143). 
Although, B. burgdorferi possesses a double membrane similar to other Gram-
negative bacteria, the LPS and phosphatidylethanolamine, which typically are found in 
Gram-negative bacteria, are absent in this organism (145, 146). Instead, B. burgdorferi 
possesses an extraordinary abundance of lipoproteins and glycolipids on its membrane 
(145, 147-149). In addition, the outer membrane contains a relatively low density of 
transmembrane proteins (150). 
Genome of B. burgdorferi. The genome of B. burgdorferi sensu stricto strain  
B31 was completely sequenced in 1997 (151), and found to be unique. The B31 
genome is composed of a small linear chromosome of 910,725 base pairs (bp) with an 
average G+C content of 28.6%. In addition to this linear chrosome, B. burgdorferi 
possesses extremely high numbers of endogenous plasmids—12 linear and 9 circular 
plasmids that total 610 kilobase pairs (kb), which is the largest number known for any 
bacterium (Fig. 1.8). The linear plasmids (lp) and circular plasmids (cp) are numbered 
according to their sizes in kb. The isolate B31 contains the following linear plasmids: 
lp5, lp17, lp21, lp25, four different homologous plasmids of 28 kb (lp28-1, lp28-2, lp28-3, 
and lp28-4), lp36, lp38, lp54, and lp56; and the following circular plasmids: cp9, cp26, 
and seven homologous plasmids of 32 kb (cp32-1, cp32-3, cp32-4, cp32-6, cp32-7, 
cp32-8, and cp32-9) (151, 152). However, comparisons with other B31 cultures suggest 
that this isolate may have lost one linear plasmid (lp21) and one or two 32 kb circular 
plasmids during growth in culture since its original isolation from the midgut of an Ixodes 
tick (151, 153-158). Among these 21 endogenous plasmids, eight plasmids (lp5, lp21, 


























Figure 1.8. The segmented genome of B. burgdorferi. Linear plasmids are 
abbreviated lp and circular plasmids cp, the number represents the approximate size 
of the plasmid in kilobase pairs. Evidence supports that plasmids shown in red are 
required for infectivity or persistence in the tick or vertebrate hosts. Sizes are not 
drawn to scale. 
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(spontaneously lost) during the in vitro propagation (159). Because these plasmids 
could not maintained in B. burgdorferi without in vivo environmental pressure, those are 
believed to be important for infectious life cycle of B. burgdorferi. For this reason, 
investigators use a low-passage strain and verify retention of endogenous plasmids 
before conducting an in vivo experiment with B. burgdorferi. The overall G+C content of 
the plasmids varies from 20.7% to 31.6% (160). 
Periplasmic flagella of B. burgdorferi. A bacterial flagellum consists of three 
basic parts; basal body, hook, and filament. Unlike other externally flagellated 
bacteria—where flagella are in the ambient environment—the flagella of spirochetes are 
located in the periplasmic space (161). Cryo-electron tomography (cryo-ET) of bacterial 
flagellar motors suggests that the architectural structure of flagellar motors between 
external flagella and periplasmic flagella are very similar, consisting of the MS-ring, C-
ring, P-ring, stator, hook, export apparatus, and the filaments (compare Fig. 1.9.A, B 
with 1.9.C, D) (162-164). However, some structures are absent in the periplasmic 
flagellar motor which observed in the extermal flagellar motor (e.g., L-ring). On the 
contrary, the periplasmic flagellar motor possess some features that are absent in all 
externally flagellated bacterial motors studied to-date. One of them is a structure called 
the collar (Fig. 1.9.D) (162, 164). The collar structure is a spirochete-specific novel 
component, located in the periplasm, that is linked to the major components of the 
flagella (162-164). 
The intact flagellar motor of B. burgdorferi consists of the C-ring, the MS-ring, the 
rod, the export apparatus, and the stator (Fig. 1.9.D). The C-ring of B. burgdorferi is 




























Figure 1.9. Comparative analysis of the intact motor between external flagella 
and periplasmic flagella. (A) In situ Salmonella enterica motor structure 
reconstructed by cryo-ET. (B) A cartoon model of S. enterica flagellar motor. (C) 
Intact motor structure of B. burgdorferi. The basal body portion is outlined in the 
intact motor. (D) A cartoon model of B. burgdorferi flagellar motor. OM, 
outermembrane; CM, cytoplasmic membrane; L, L-ring; R, rod; P, P-ring; MS, MS-
ring; EXP. export apparatus. 
34 
 
FliN. The C-ring or switch complex is important for switching motor rotation from 
clockwise (CW) to counter-clockwise (CCW) or vice versa. Motor switching occurs when 
chemotaxis response regulator CheY binds to FliM and FliN (below). The MS-ring is 
composed of FliF. The MS-ring acts as a platform for assembly of the C-ring, the stator, 
and the flagellum-specific type III secretion apparatus (Fig. 1.10, 1st panel). The rod is a 
multiprotein complex that assembles in the order FliE-FlgB-FlgC-FlhO-FlhG (Fig. 1.10, 
2nd and 3rd panels) (163). This flagellar rod functions as an export channel of hook and 
flagellin proteins, and drive shaft. The stator is composed of the MotA and MotB 
proteins, and generated flagellar mechanical movement by proton gradients across the 
membrane. B. burgdorferi contains 16 stator units around the C-ring rotor. The 
cytoplasmic domain of the stator is adjactent to the C-terminal domain of the FliG switch 
protein. This stator-rotor interaction induces a conformational change of FliG, which is 
likely to be a fundamental mechanism for flagellar rotation (163). FliL is localized 
between the stator and the rotor, which is partially involved in the proper orientation of 
periplasmic flagella in B. burgdorferi (165). 
The flagellar hook of B. burgdorferi is 61 nm long hollow tube structure consisting 
of FlgE polymer (approximately 133 units) (166). The hook serves as a universial joint 
connecting the flagellar filament to the basal body (167), however, the FlgE subunits in 
B. burgdorferi are covalently cross-linked to form a stable high-molecular weight 
complex (over 250 kDa; FlgE monomer ~50 kDa). This covalent cross-linked FlgE hook 
in spirochetes may be important for providing structural strength during rotation within 
the periplasm (168). Hook assembly is mediated by the hook-cap FlgD (Fig. 1.10, 3rd 




















Figure 1.10. A model of flagellar assembly in B. burgdorferi. In the pre-type III secretion (T3S) assembly state, 
many flagellar components assemble, including the MS-ring, the C-ring, the stators, the export apparatus, and the 
collar. The secretion channel in the MS-ring is closed (first panel). In the presence of FliE and FlgB, rod substrates 
can be secreted but are unable to form a stable structure until all of the proximal rod substrates (FliE, FlgB, FlgC, 
and FlhO) are present (second panel). The distal rod protein FlgG adds onto the proximal rod and polymerizes until 
it reaches a determined length (third panel). A hook cap composed of FlgD forms at the distal end of the rod (third 
panel) and promotes hook assembly (forth panel). Assembly of the filament (FlaA and FlaB) is promoted by the 














The flagellar filaments are assembled on top of the hook and are composed of a 
major filament protein FlaB (41 kDa) and a minor filament protein FlaA (38 kDa) (169-
171). Filament assembly is mediated by the filament-cap protein FliD (Fig. 1.10, 4th and 
5th panels) (163). FlaB monomers are secreted into the periplasmic space by the 
flagellar-specific type III secretion pathway, and form the flagellar filament core. The 
periplasmic flagella have a major role in not only motility, but also in morphology of B. 
burgdorferi. Previous studies revealed that the major periplasmic flagellin, encoded by 
flaB, is essential for the motility and wave-like morphology of the cells. Without the 
periplasmic flagella (in a flaB mutant), spirochetes show a non-motile, rod-shaped 
morphology, instead of being a motile and wave-like shaped as the wild-type (Fig. 1.7.A. 
right) (143, 172). In contrast to FlaB, FlaA excretes using the Sec-mediated pathway. 
FlaA forms the sheath surrounding the FlaB core near the hook (171). The role of FlaA 
is unknown, but recent unpublished data with a ΔflaA mutant indicates that the mutant 
displays reduced motility compared to the wild-type cells (Motaleb et al., unpublished). 
In other bacteria, such as E. coli or Salmonella, the motility and chemotaxis 
genes are tightly regulated by a transcriptional hierarchy (regulatory cascade class I, II, 
and III) (173). In contrast, B. burgdorferi does not employ a transcription cascade to 
regulate its motility and chemotaxis genes. It is noteworthy to mention that all the 
motility and chemotaxis genes of B. burgdorferi identified thus far fall under the 
regulation of the housekeeping sigma factor (σ70) (138). However, our understanding of 
the regulation of motility and chemotaxis gene expression in B. burgdorferi is still very 
limited. 
Recent studies indicated that the borrelial carbon storage regulator A (CsrA) is a 
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regulator of transcriptional control of the major flagellin flaB gene expression in B. 
burgdorferi (174). The two-component regulatory system called HK2/Rrp2 and its 
downstream transcriptional factors RpoN and RpoS (the Rrp2-RpoN-RpoS pathway) 
are involved in motility and chemotaxis gene expression in B. burgdorferi (175-179). 
The second messenger, 3’, 5’-cyclic-diguanosine monophosphate (c-di-GMP), also 
controls motility and chemotaxis (180-183). Translational control of motility gene 
expression appears to be important, with CsrA and c-di-GMP emerging as major 
regulator of motility and chemotaxis. However, many questions, such as what is the 
interplay between the identified regulatory elements in modulating gene expression and 
how do environmental signals play a role in differential gene expression within the 
different hosts, remain unanswered. 
Motility and chemotaxis of B. burgdorferi. Chemotaxis and motility genes 
comprise approximately 5-6% of the genome of B. burgdorferi, suggesting the 
importance of these functions in its life cycle (138, 151). Indeed, motility and chemotaxis 
are found to be esential for host tissue colonization or disease production by many 
bacteria, including the spirochetes (138, 143, 184-194). While motility and chemotaxis 
has been extensively studied in other bacteria such as E. coli (195-197), the chemotaxis 
system of B. burgdorferi and the motility, which is generated by rotation of the 
periplasmic flagella are poorly understood. B. burgdorferi contains 7–11 periplasmic 
flagella inserted at each pole of the cell, and those periplasmic flagella form a tight 
packed ribbon that causes the outer membrane to bulge (Fig. 1.7.B). Periplasmic 
flagellar filaments wrap around the cell cylinder as they extend toward the other pole of 
the cell (137, 138, 198). B. burgdorferi has four different motility modes based on the 
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direction of flagellar rotation: two translational modes and two non-translational modes 
(Fig. 1.11). The periplasmic flagella of the two ribbons rotate asymmetrically during 
translational mode. In this mode, the periplasmic flagella of the anterior ribbon rotate 
counter-clockwise (CCW), and those of the posterior ribbon rotate clockwise (CW) (Fig. 
1.11.A, top). Reversals occur when the periplasmic flagella of both ribbons change the 
direction of rotation (Fig. 1.11.A, bottom). In contrast, both periplasmic flagella ribbons 
rotate in the same direction (both rotate either CW or CCW) in the non-translational 
modes (Fig. 1.11.B). This asymmetric mode of motility is unique to the spirochetes (138, 
169). When the flagellar motors are engaged at each end of the bacteria, they impart a 
wave-like morphology and an unusual “corkscrew-like” locomotion. This unusual motility 
pattern is believed to be important for efficient motility within the dense tissues through 
which these spirochetes preferentially disseminate in both vertebrate and arthropod 
hosts (186). Interestingly, swimming speed of B. burgdorferi increases substantially as 
the concentration of viscous material such as methylcellulose or hyaluronate is 
increased in the in vitro viscoelastic medium (199). The increasing swimming speed in a 
higher viscosity environment suggests that B. burgdorferi motility may be optimized for 
migration through host tissues. 
Chemotaxis allows bacteria to follow gradients of nutrients and other 
environmental stimuli. The components of the chemotaxis signal transduction systems 
that mediate these responses are highly conserved among prokaryotes. The best- 
studied system is that found in E. coli (200) (Fig. 1.12). In this model bacterium, 
membrane-spanning methyl-accepting chemotaxis protein receptors (MCPs) are 


























Figure 1.11. Swimming cells of B. burgdorferi as a function of the direction in 
which the periplasmic flagella rotate. Straight arrows at cell ends indicate 
direction of swimming. Curved arrows indicate the direction in which the periplasmic 
flagella rotate. For simplification, only one periplasmic flagella is shown attached at 
each end of protoplasmic cell cylinder. Panel (A) shows translational forms, and 



























Figure 1.12. The Escherichia coli chemotaxis pathway.  (A) Changes in 
chemoeffector levels are detected by transmembrane chemoreceptors. These signal 
through CheW to the chemotaxis histidine protein kinase, CheA. In response to 
decreased attractant concentration, the chemoreceptors activate CheA 
autophosphorylation. Phosphorylated CheA (CheA-P) phosphorylates either of its 
cognate response regulators, CheB and CheY. CheY-P binds to the flagellar motor 
and promotes a switch in the direction of rotation from counter-clockwise to 
clockwise. CheB-P is a methylesterase that mediates adaptation in conjunction with 
the chemotaxis methyltransferase, CheR. CheZ is a specific phosphatase that 
dephosphorylates CheY-P, allowing rapid signal termination.  (B) Switching of the 
bidirectional Escherichia coli flagellar motor. The counter-clockwise and clockwise 
conformations of the motor exist in equilibrium. In the absence of CheY-P, counter-
clockwise rotation is strongly favoured. CheY-P binding to FliM and FliN 
(components of the switch complex) shifts the equilibrium in favour of clockwise 
rotation. There are believed to be ~34 binding sites for CheY-P, and as more of these 



























CheA is regulated by occupancy of these MCPs with a ligand (e.g., an attractant or 
repellent). CheA uses ATP to autophosphorylate, and the phosphate group is then 
transferred to the response regulator CheY. The phosphorylated CheY (CheY-P) binds 
to the flagella motor switch protein FliM and FliN (201, 202). This binding results in the 
change of direction of the flagella from the default counter-clockwise (running motility) to 
clockwise rotation, resulting in tumbling motility (no net movement of bacteria). Binding 
of attractant to the MCPs decreases the kinase activity of CheA, resulting in reduced 
CheY-P and tumbling frequency. The concentration of CheY-P determines whether a 
cell runs (requiring high CheY-P) or tumbles (low CheY-P). The chemotaxis system 
adapts to persistent modification via receptor methylation by methyltransferase CheR 
(positive stimuli) and demethylation by methylesterase CheB (negative stimuli). CheR 
and CheB are the only known chemoreceptor modification enzymes in this model (203). 
Even though the components of the chemotaxis signal transduction system are highly 
conserved among prokaryotes, the chemotaxis pathway in B. burgdorferi differs from 
other well-studied bacterial models and is more complicated due to the presence of 
multiple copies of chemotaxis genes, including six mcp, two cheA, three cheY, two 
cheB, two cheR, and three cheW (Fig. 1.13). It has only one CheY-P phosphatase 
(CheX) which is commonly found in bacteria. B. burgdorferi also has a putative gene 
encoding CheD, which is not found in E. coli (151). CheD is relatively well-characterized 
in Bacillus subtilis and Thermotoga maritima, where it plays an important role in 
chemotaxis by modification of MCPs by deamidation or by enhancing CheC 
phosphatase activity, thereby regulating the levels of the CheY-P response regulator 




















Figure 1.13. Model of the B. burgdorferi chemotaxis system. A simplistic 
chemotaxis signaling pathway of B. burgdorferi. The genome of B. burgdorferi 
encodes multiple homologs of several chemotaxis genes (e.g. six mcp, two cheA, 
three cheW, three cheY, two cheB, and two cheR genes), making it more complex 
than other bacteria. The role of most borrelial chemotaxis proteins are still unknown. 
To date, only two studies have shown that chemotaxis—specifically involving the 
histidine kinase cheA2 (box 1) and chemotaxis response regulator cheY3 (box 2)—
are essential for the infectious life cycle of B. burgdorferi (189, 209). CheY2 may 
serve as a regulator for a virulence determinant in B. burgdorferi (box 3) (Xu et al., 
manuscript in progress). The role of cheY1 and other putative chemotaxis genes in 
































































B. burgdorferi are phosphorylated by both the histidine kinases, CheA1 and CheA2 
(208). However, only cheY3 was found to be essential for motility and chemotaxis in 
vitro (208). Recently, cheY3-mediated chemotaxis is also found to be crucial for motility 
in vivo, dissemination, and viability of B. burgdorferi in mice and ticks (Fig. 1.13, dotted 
lined box 2) (209). Interestingly, the CheY proteins do not functionally overlap with each 
other (208). The cheY2 mutant cell was not defective in motility or chemotaxis in vitro, 
survived normally in ticks, and those mutant-infected ticks transmitted the spirochetes 
into mice (208, Xu et al., manuscript in progress). However, the cheY2 mutant 
spirochetes are considerably attenuated in murine infection via both needle injection 
and tick transmission (Xu et al., manuscript in progress). It is unclear as to why the 
cheY2 mutant spirochetes show attenuation in mouse infection, but not in the tick hosts. 
We assume that CheY2 may function distinctively from most other typical chemotaxis 
signaling systems such as either binding to an operon promoter or a protein to modulate 
the expression or activity of some virulence determinants in B. burgdorferi (Fig. 1.13, 
dotted lined box 3). Intensive studies are required to identify the role of B. burgdorferi 
putative chemotaxis proteins. 
STATEMENT OF THE PROBLEM, GOAL, 
SPECIFIC OBJECTIVES, AND HYPOTHESES 
This dissertation research mainly focused on motility and chemotaxis of B. 
burgdorferi, and the research goal was divided into two sections: 1) Determining the role 
of B. burgdorferi CheD in motility, chemotaxis, and mouse/tick-mouse models of B. 
46 
 
burgdorferi; and 2) Discovery and characterization of the novel spirochete flagellar 
proteins in B. burgdorferi. 
Motility and chemotaxis are reported to be crucial for the infectious life cycle of B. 
burgdorferi (143, 186, 188, 190, 191, 194). After transmission from tick to mammalian 
host, B. burgdorferi must quickly perceive its new local environment and make the 
appropriate adaptations, rapidly disseminating through skin tissues to evade the cellular 
immune response and migrating to appropriate target tissues that allow for persistence 
and evasion of the expanding adaptive immune response. After residing in this 
mammalian host for weeks to years, B. burgdorferi must then be able to detect that a 
new tick vector has attached to host skin, and then rapidly migrate to the bite site, and 
enter the vector via the blood meal before the tick feeds to repletion and detaches. Until 
now, only two chemotaxis genes [cheA2 (189), and cheY3 (209)] have been studied in 
the B. burgdorferi infectious life cycle. A rigorous study is needed in order to understand 
the function of other putative chemotaxis genes. 
Chapter 2 of this dissertation focuses on the putative genes encoding CheD. We 
hypothesize that cheD plays an important role in B. burgdorferi motility, chemotaxis, and 
in the mouse-tick-mouse life cycle of the spirochete. In chapter 2, we have 
characterized the cheD mutant in detail. Moreover, we have shown the role of cheD in 
B. burgdorferi. This study is the first investigation of CheD in the disease process. Our 
studies provide more information in understanding the chemotaxis signaling pathway of 
the spirochete. Dissecting the roles of cheD may provide clues as to how the spirochete 
achieves asymmetric modes of motility. 
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Motility and chemotaxis are intimately interlaced as the chemotaxis response 
regulator, CheY, binds to the periplasmic flagellar switch proteins to control motor 
rotation. In addition to chemotaxis, this dissertation research project also focuses on 
demonstrating the roles of unique periplasmic flagellar proteins in motility in B. 
burgdorferi. Unlike externally flagellated bacteria, B. burgdorferi possesses periplasmic 
flagella that contain a novel structural component called the collar (162, 164). Recent 
cryo-ET analyses revealed that the collar structure is conserved among the spirochetes 
but is absent from all other flagellated bacteria (162-164). However, nothing is known 
about the proteins encoding the collar or their function in any spirochete. The collar 
proteins are hypothesized to play an important role in motility, flagellar assembly as well 
as for providing proper rigidity and flexibility of flagella within the periplasmic space 
during rotation. 
Chapter 3 focuses on the B. burgdorferi gene flbB, which we identified to be 
involved in collar assembly through an exhaustive search. This chapter describes the 
role of flbB in motility, cell morphology, periplasmic flagellar orientation, and assembly of 
other motor structures. Moreover, using various comprehensive approaches, several 
additional proteins are identified. These proteins are potential candidates for the 
spirochete-specific collar structure. Our studies clearly indicate that the B. burgdorferi 
genome possesses additional genes encoding the periplasmic flagella. However, these 
newly identified genes were annotated as hypothetical or “function unknown” in the B. 
burgdorferi genome (151). 
CHAPTER TWO: BORRELIA BURGDORFERI CHED 
PROMOTES VARIOUS FUNCTIONS IN CHEMOTAXIS AND 
THE PATHOGENIC LIFE CYCLE OF THE SPIROCHETE 
ABSTRACT 
Borrelia burgdorferi possesses a sophisticated chemotaxis signaling system, 
however, the role of the majority of the chemotaxis proteins in the infectious life cycle 
has not yet been demonstrated. Specifically, the role of CheD during host colonization 
has not been demonstrated in any bacterium. Here, we systematically characterized the 
B. burgdorferi CheD homolog using genetics, biochemical, and mouse-tick-mouse 
infection cycle studies. Bacillus subtilis CheD plays an important role in chemotaxis by 
deamidation of methyl-accepting chemotaxis protein receptors (MCPs) and by 
increasing the receptor-kinase activity or enhancing CheC phosphatase activity, thereby 
regulating the levels of CheY response regulator. Our biochemical analysis indicates 
that B. burgdorferi CheD significantly enhances CheX phosphatase activity by 
specifically interacting with the phosphatase. Moreover, CheD specifically binds two of 
the six MCPs, indicating that CheD may also modulate the receptor proteins. Although 
the motility of the cheD mutant cells was indistinguishable from the wild-type cells, the 
mutant did exhibit reduced chemotaxis. Importantly, the mutant showed significantly 
reduced infectivity in C3H/HeN mice via needle inoculation. Mouse-tick-mouse infection 
assays indicate that CheD is dispensable for acquisition or transmission of spirochetes, 
however, the viability of cheD mutants in ticks is marginally reduced compared to the 
wild-type or complemented cheD spirochetes. These data suggest that CheD plays an 
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important role in chemotaxis and pathogenesis of B. burgdorferi. We propose potential 
connections between CheD, CheX, and MCPs, and discuss how these interactions play 




Borrelia burgdorferi, the causative agent of Lyme disease cycles between Ixodes 
ticks and a mammalian host.  Motility and chemotaxis are known to be required for host 
tissue colonization or disease production by many bacteria, including the spirochetes; 
however, these processes have not been rigorously characterized in any spirochete 
(138, 143, 184-194). B. burgdorferi is a spirochetal motile bacterium that contains a 
sophisticated and complicated chemotaxis signal transduction system. This spirochete 
is a long (10-20 μm) and thin (0.33 μm) organism with flat-wave morphology, and its 
motility is provided by flagella that are located within the periplasm. There are 7-11 
periplasmic flagella inserted at each pole of the cell forming a ribbon-like structure that 
wraps around the cell cylinder as they extend toward the other pole of the cell (138, 
188, 190). When the periplasmic flagellar motors rotate asymmetrically [i.e., flagella at 
one pole rotate in clockwise (CW) and the flagella in other pole rotate in counter-
clockwise (CCW)] the spirochete runs. When the flagellar motors at both poles of the 
cell rotate in the same direction (both in CW or CCW), B. burgdorferi cells flex with no 
net translocation (210). This manner of swimming also produces an unusual 
“corkscrew-like” locomotion. This distinctive motility pattern is believed to be important 
for efficient migration within the dense tissues through which these spirochetes 
preferentially disseminate in both vertebrate and arthropod hosts (138, 211). 
Interestingly, where most externally flagellated bacteria either slow down or stop within 
viscous material (212, 213), the velocities of spirochetes actually increase within 
viscous media (214-216), thus empowering the spirochetes to penetrate into tissues 
that other bacteria fail to invade. 
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Chemotaxis is also believed to be very important for the complex vector-host life 
cycle utilized by B. burgdorferi. After transmission from tick to mammalian host, B. 
burgdorferi must quickly perceive its new local environment and make the appropriate 
adaptations, rapidly disseminating through skin tissues to evade the cellular immune 
response and migrating to appropriate target tissues, which allows for evasion of the 
expanding adaptive immune response and survival. After residing in this mammalian 
host for weeks to years, B. burgdorferi must then be able to detect that a new tick vector 
has attached to host skin, and then rapidly migrate to the bite site and enter the vector 
(54).  
Chemotaxis allows bacteria to follow gradients of nutrients and other 
environmental stimuli by governing their motility. The components of the chemotaxis 
signal transduction systems that mediate these responses are highly conserved among 
prokaryotes. The best studied system is found in Escherichia coli (or Salmonella 
enterica serovar Typhimurium) (203, 217, 218). In this model organism, membrane-
spanning methyl-accepting chemotaxis protein receptors (MCPs) detect environmental 
signals. These MCP proteins are coupled to a histidine kinase (CheA) and a linker 
protein CheW. The catalytic activity of CheA is regulated by occupancy of these MCPs 
with a ligand (e.g. an attractant or repellent). CheA uses ATP to autophosphorylate, and 
the phosphate group is then transferred to the response regulator CheY. The 
phosphorylated CheY (CheY-P) then binds to the flagella motor switch proteins FliM 
and FliN (201). This binding results in the change of direction of the flagella from the 
default CCW (running motility) to CW rotation, resulting in tumbling motility. Binding of 
attractant to the MCPs decreases the kinase activity of CheA, resulting in reduced 
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CheY-P as well as tumbling frequency. The concentration of CheY-P determines 
whether a cell runs (requires low CheY-P) or tumbles (high CheY-P). CheY-P is able to 
be autodephosphorylate, however, the phosphatase CheZ efficiently dephosphorylate 
the levels of CheY-P in E. coli (219). This phosphorylation-dephosphorylation is crucial 
for the bacterial cells to respond appropriately to the environmental stimuli. The 
chemotaxis system adapts to persistent modification via receptor methylation by 
methyltransferase CheR (positive stimuli) and demethylation by methylesterase CheB 
(negative stimuli). CheR and CheB are the only known chemoreceptor modification 
enzymes in this E. coli model (203).  
Even though the components of the chemotaxis signal transduction system are 
conserved among prokaryotes, the chemotaxis pathway in B. burgdorferi differs from 
the other well-studied bacterial models and is much more complicated due to the 
presence of multiple copies of chemotaxis genes, including six mcp, two cheA, three 
cheY, two cheB, two cheR, and three cheW genes—which may contribute to the 
asymmetric motility of the spirochete. Moreover, B. burgdorferi has a putative gene 
encoding CheD, which is not found in E. coli (138). CheD is relatively well characterized 
in Bacillus subtilis and Thermotoga maritima (204-207). In B. subtilis, CheD plays an 
important role in motility and chemotaxis. A cheD mutant displays a distinctive motility 
pattern: wild-type cells exhibit running and tumbling motility, whereas the ΔcheD 
constantly tumbles. At the molecular level, CheD interacts with the receptor MCPs. 
MCP proteins contain the well-conserved substrate-binding site of CheD, A/S-X-X-Q/E-
Q/E-X-X-A/S (A, alanine; S, serine; Q, glutamine; E, glutamate; X, any amino acid). 
CheD modifies the MCPs by deamidating glutamine to glutamate residues. The 
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deamidation by CheD is required for the B. subtilis chemoreceptors to effectively 
transduce signals to the CheA kinase (206, 220). Additionally, CheD interacts with the 
phosphatase CheC, enhancing its enzymatic activity and fine-tuning the intracellular 
concentration of CheY-P (204, 206) B. burgdorferi possesses a phosphatase, CheX, 
that has been previously reported to possess CheY-P dephosphorylating activity, and 
that the cheX mutant cells constantly flexes (221-223). It is noteworthy to mention that 
the “flex” of B. burgdorferi is considered to be equivalent to the tumbling phenotype 
seen in E. coli. Moreover, the MCPs of B. burgdorferi contain the well-conserved 
potential substrate-binding sites of CheD (183, 206, 220). These observations lead us to 
hypothesize that CheD in B. burgdorferi plays a role similar to its counterpart in B. 
subtilis. Most importantly, even though the role of CheD in motility and chemotaxis has 
been demonstrated in other bacteria, its role in pathogenesis has not been reported in 
any organism. To-date, only one chemotaxis (cheA2) gene has been investigated in the 
B. burgdorferi infectious life cycle (i.e., tick to mouse transmission) (189). A rigorous 
study is therefore warranted in order to understand the function of other putative 
chemotaxis genes. 
In this study, we determine the requirement of cheD in motility and chemotaxis in 
B. burgdorferi by inactivating the cheD gene as well as by demonstrating its enzymatic 
role in chemotaxis signaling system. Moreover, we define the role of cheD in the 
disease process (mouse-tick-mouse infection cycles) for the first time. We show that 
CheD is important in not only chemotaxis as it enhances the CheX phosphatase activity, 




MATERIALS AND METHODS 
 Ethics statement. East Carolina University is accredited by the International 
Association for Assessment and Accreditation of Laboratory Animal Care. Protocols for 
tick and animal experimentations were approved by the East Carolina University animal 
care and use committee. 
 Bacterial strains, plasmids, and growth conditions. The bacterial strains and 
plasmids used in this study are listed in Table 2.1. Low-passage, virulent B. burgdorferi 
strain B31-A3 was used as a wild-type clone throughout the study (224, 225). The 
genome of the virulent B31 strain was found to contain a total of 21 plasmids, with 12 
linear and 9 circular plasmids, in addition to its 960-kb linear chromosome (151, 152). 
Clone B31-A3 lacks circular plasmid 9 (cp9) but remains infectious in tick-mouse cycle 
studies (225, 226). Constructions of cheD mutants and its complemented strains are 
described below. B. burgdorferi cells were cultured in liquid Barbour-Stoenner-Kelly 
(BSK-II) medium, and plating BSK was prepared using 0.5% agarose (143, 227, 228). 
Cells were grown at 35°C in a 2.5% CO2 humidified incubator as described previously 
(143, 225, 227). Antibiotics, when required, were included in the B. burgdorferi culture 
medium with the following concentrations: 200 μg/ml kanamycin, 40 μg/ml gentamicin, 
100 μg/ml streptomycin. Escherichia coli cells were grown at 37°C in Luria-Bertani (LB) 
broth or LB agar (229). Antibiotics, when required, were included in the E. coli culture 
medium with the following concentrations: 100 μg/ml ampicillin, 35 μg/ml 
chloramphenicol, 100 μg/ml spectinomycin. 
Construction and complementation of the cheD mutant. Construction of the 
cheD inactivation plasmids, electroporation, and plating conditions were described 
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Table 2.1. Bacterial strains and plasmids used in this study 
Strains or Plasmids Relevant characteristics* Reference or Source 
Borrelia burgdorferi   
B. burgdorferi B31-A3 B31 (ATCC 35210), the prototype 
strain of B. burgdorferi sensu 
stricto, originally isolated from a 
tick collected on Shelter Island, 




B. burgdorferi B31-A3 
ΔcheD 
 
B31-A3 derived, ΔcheD, KanR This study 
B. burgdorferi B31-A3 
cheDcom 
B31-A3 ΔcheD derived, 
integrated PcheD-cheD within the 
intergenic region of bb0445 and 
bb0446, KanR GentR 
 
This study 
B. burgdorferi B31-A3 
ΔcheY3 
 
B31-A3 derived, ΔcheY3, KanR Lab collection 
(209) 
   
Escherichia coli   
E. coli DH5α Transformation host for cloning 
vector, F- Φ80dlacZΔM15, 
Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17(rk-,mk+) phoA, 
supE44 thi-1 gyrA96 relA1 
 
Promega Inc. 
E. coli BL21 (DE3) Host for overexpression, F- ompT 
hsdSB (rB-,mB-) gal dcm (DE3) 
 
Promega Inc. 
E. coli M15 Host for overexpression, F-




   
Plasmids   
pGEM-T Easy Cloning vector for PCR product, 
ColE1 ori, AmpR 
 
Promega Inc. 
pXLF14301 Suicide vector, pUC ori, AmpR 
 
(183, 230, 231) 
 
pASK-IBA7+ Overexpression vector, Strep-tag, 






Table 2.1. Bacterial strains and plasmids used in this study (~continue) 
Strains or Plasmids Relevant characteristics* Reference or Source 
Plasmids   
pMAL c2x Overexpression vector, MBP-tag, 
pBR322 ori, AmpR 
 
NEB Inc. 
pQE30 Overexpression vector, 6xHis-
tag, ColE1 ori, AmpR 
 
Qiagen Inc. 
Teasy::cheD_KO cheD-PflgB-aph1 in pGEM-T Easy 
for cheD knockout, AmpR 
 
This study 
pXLFCheD PcheD-cheD in pXLF 14301 for 
cheD complementation, AmpR 
 
This study 




c2x::MCP3 mcp3 cytoplasmic domain 




c2x::MCP4 mcp4 cytoplasmic domain 




c2x::MCP5 mcp5 cytoplasmic domain 


















Teasy::enolase-RT enolase-RT in pGEM-T Easy for 
qRT-PCR, AmpR 
Lab collection 






previously (143, 172). Briefly, the cheD gene (locus number bb0606) and flanking DNA 
was first amplified by PCR from the chromosomal DNA of B. burgdorferi strain B31-A3 
using primers CheD-KO-F (GGAATCAGGCTTAAATCTTG) and CheD-KO-R 
(AAGCATGGAAAGTTGAAACC). The PCR product was cloned into plasmid pGEM-T 
Easy (Promega Inc.). The cheD gene was inactivated using a kanamycin resistance 
cassette (PflgB-aph1) (224), which was inserted at the HindIII sites located within cheD. 
Competent B31-A3 cells were electroporated with cheD-PflgB-aph1 DNA that was 
linearized by NotI restriction digestion to remove the ampicillin restriction marker of the 
vector, preventing it from being introduced into B. burgdorferi (143, 172). The 
transformants were selected with kanamycin, and the kanamycin-resistant 
transformants were confirmed by PCR to have the PflgB-aph1 integrated within the cheD 
(143, 172, 182). Confirmation of the cheD gene inactivation was achieved by the lack of 
cheD transcripts in the cheD mutant cells (ΔcheD) by quantitative reverse transcriptase-
PCR (qRT-PCR; see below). 
The cheD mutant was complemented in cis by genomic integration using 
pXLF14301 suicide vector (183, 230, 231). To complement the mutant, the cheD gene 
and its native promoter (PcheD) DNA sequences were PCR amplified from genomic DNA 
of B. burgdorferi strain B31-A3 using primers CheDcom.-F 
(AATTAAAATGATTTAACATATTTCCCAATAACATAGATAC) and CheDcom.-R 
(GCGGCCGCTTAAAAAACCTTTGTTCC), and PcheD-F 
(ACTAGTATTGGCCATATCCCCATTAAGGC) and PcheD-R 
(GTATCTATGTTATTGGGAAATATGTTAAATCATTTTAATT), respectively. The 
amplified DNA fragments were ligated by overlapping PCR, yielding PcheD-cheD DNA 
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fragment, and then cloned into plasmid pGEM-T Easy (Promega Inc.). Finally, PcheD-
cheD was excised from the pGEM-T Easy using SpeI and NotI restriction digestions and 
then cloned into pXLF14301, yielding plasmid pXLFCheD. The plasmid was then 
electroporated into the ΔcheD mutant cells followed by selection with gentamicin and 
kanamycin. The resistant clones were analyzed by PCR for integration of PcheD-cheD 
within the intergenic region of bb0445 and bb0446. Restoration of cheD expression in 
the complemented cheD (cheDcom) clones was also verified by qRT-PCR (see below). 
Retention of B. burgdorferi endogenous plasmids in wild-type, mutant, and the 
complemented strains was verified by PCR as described previously (143, 182, 183, 
225).  
Reverse transcription-polymerase chain reaction (RT-PCR). Exponentially 
growing B. burgdorferi wild-type cells (2 x 107 cells/ml) were treated with RNAprotect™ 
followed by total RNA isolation using the RNeasy mini kit (Qiagen Inc.). Contaminating 
DNA in the RNA samples was removed by RNase-free Turbo®  DNase I (Ambion Inc.) 
digestion for 3 hr. at 37°C followed by RNeasy mini purification. For RT-PCR, cDNA 
was prepared from 1 μg RNA using the AffinityScript QPCR cDNA synthesis kit (Agilent 
Technologies Inc.) according to the manufacturer's protocol. The iCycler detection 
system (Bio-Rad Inc.) was used to measure cheD transcript levels according to the 
manufacturer’s instructions. B. burgdorferi enolase was used as a reference gene (171, 
181-183). The gene specific primers (5’-3’) were RT-enolase-F 
(TGGAGCGTACAAAGCCAACATT); RT-enolase-R 
(TGAAAAACCTCTGCTGCCATTC); CheD-qRT-F (CCTGGTGAAGCTTTTGTTTC); and 
59 
 
CheD-qRT-R (TTGATCAGGAGATATGTCAAGATC). The relative level of expression 
was calculated using the 2-ΔΔCT method (181-183, 232, 233).  
Recombinant protein expression in E. coli. In order to express B. burgdorferi 
cheD in E. coli,  a DNA fragment harboring the entire cheD open reading frame was 
amplified from chromosomal DNA of B31-A3 using primers R.CheD-F 
(TTAAATCATTTTAATTTTAA) and R. CheD-R (TTAAAAAACCTTTGTTCCGT), and 
cloned into the pASK-IBA7+ expression vector (IBA Inc.) to generate the Strep-Tactin 
tagged CheD (Strep-CheD). E. coli BL21 (DE3) harboring the pASK-IBA7+::cheD was 
induced with 200 ng/ml of anhydrotetracycline. Expression and purification of E. coli 
CheA, B. burgdorferi His-CheY3 and His-CheX proteins were described elsewhere 
(208, 222, 234). B. burgdorferi mcp3, mcp4, and mcp5 open reading frames were 
cloned separately in the expression vector pMAL c2x (NEB Inc.) to generate MBP-
MCP3, MBP-MCP4, and MBP-MCP5 recombinant proteins, respectively. E. coli codon-
plus cells harboring pMAL c2x::mcp3, mcp4 or mcp5 was expressed and purified 
according to the manufacturer’s protocol (NEB Inc.).The purity of the recombinant 
proteins were verified by Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and quantified by comparison with standard bovine serum albumin (BSA). 
SDS-PAGE and immunoblot analyses. SDS-PAGE and immunoblotting with an 
enhanced chemiluminescent detection method (GE Health Inc.) were carried out as 
reported previously (143, 172). The concentration of protein in cell lysates was 
determined by a Bio-Rad protein assay kit using BSA as a standard. Unless otherwise 
noted, 5 μg of lysate protein was subjected to SDS-PAGE and immunoblotting using B. 
burgdorferi specific antibodies. 
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 Affinity blotting. Protein-protein interactions were determined using affinity 
blotting (235). Briefly, 2 μg of purified recombinant Strep-CheD protein was subjected to 
SDS-PAGE, and transferred to polyvinylidene difluoride (PDVF) membrane. The 
membranes were blocked overnight with shaking at 4°C in blocking solution (5% skim 
milk, 0.9% NaCl, 10 mM Tris, pH 7.4). After the incubation, 10 μg of purified His-CheX, 
His-CheY3, MBP-MCP3, MBP-MCP4, or MBP-MCP5 was added to the blocking 
solution for 3 hr. (235). The membranes were washed 4 times with immunoblotting 
wash buffer and then probed with proper antibodies. Detection was performed with the 
ECL immunoblotting detection kit (GE Healthcare Inc.). 
 Phosphorylation assays. Phosphorylation of CheA, phosphotransfer from 
CheA-P to CheY3, and dephosphorylation of CheY3-P by CheX phosphatase have 
been described (208, 221, 222). B. burgdorferi has two CheA proteins, CheA1 and 
CheA2, and both are capable of autophosphorylation by ATP (208). However, the 
expression level of B. burgdorferi CheA1 or CheA2 in E. coli is poor and they are also 
difficult to purify in native conditions (221). Alternatively, we performed the 
autophosphorylation assays using E. coli CheA. Purified E. coli CheA was kindly 
provided by Dr. Ruth Silversmith (University of North Carolina, Chapel Hill, NC) (236). 
To generate radio-labeled phosphorylated CheA (CheA-32P), 20 pmole of purified CheA 
was incubated with 10 μCi of [γ-32P]ATP and 30 mM of non-radio-labeled ATP for 30 
minutes at room temperature. Autophosphorylated CheA was applied to Bio-Spin6 
columns according to the manufacturer's instructions to remove unincorporated [γ-
32P]ATP (208, 222). CheA-32P was then incubated with 160 pmole of purified CheY3 for 
5 minutes, as described (208, 221). The CheA and CheY3 reaction mixture was then 
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incubated with 0.15 pmole of CheX or 0.15 pmole of CheX plus 15 pmole of CheD for 
various length of time. In vitro phosphorylation reactions were conducted in the TKM 
buffer (50 mM Tris-HCl, 50 mM KCl, 5 mM MgCl2, pH 8.5), and reactions were stopped 
using the stop buffer (50 mM Tris-HCl, 100 mM dithiothreitol, 2% (w/v) SDS, 0.1% (w/v) 
bromophenol blue, 10% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol, pH 6.8). Reactions 
were subjected to SDS-PAGE. The gels were dried, and the CheY3-32P 
dephosphorylation levels were analyzed by phosphorimage analysis using Typhoon 
9410 Phosphor Imager/Fluorescence Imager (GE Healthcare Inc.) (208, 221). The 
intensity of phosphorylated proteins was calculated using Quantity One 1-D Analysis 
Software ver. 4.6.9 (Bio-Rad Inc.) and is expressed as relative “volume”. 
Dark-field microscopy, swarm plate chemotaxis assays, and colony swarm 
plate assays. Growing B. burgdorferi cells were imaged using a Zeiss Imager M1 dark-
field microscope connected to a digital camera to determine morphology and motility. 
Swarm plate assays were performed to determine the spirochete’s chemotactic ability 
as described previously (222, 227). Briefly, approximately 1 x 106 cells in a 5 μl volume 
were spotted into 0.35% agarose plates containing BSK medium diluted in 1:10 in 
Dulbecco’s phosphate-buffered saline. Since B. burgdorferi is a slow-growing organism 
with a 5 to 12 h generation time (142), swarm plates were incubated for 5 days. 
Swarming images were documented using a digital camera (143, 165, 181, 182). To 
determine an individual colony’s swarm ability, B. burgdorferi clones were plated on 
separate semi-solid BSK plates (20-50 colonies per plate). Approximately a month after 
the inoculation, swarming diameter of each individual colony was measured. Each 
isolate was assayed in at least two independent experiments. 
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 Mouse infection studies. Six to seven weeks old Mus musculus C3H/HeN mice 
were used for infection studies, as described (143, 181, 183, 225, 237). For infection via 
needle, 5 x 102 to 5 x 106 in vitro-grown spirochetes were injected intraperitoneally (143, 
225, 238). The number of spirochetes was determined using a Petroff-Hausser chamber 
and each clone was verified for their retention of endogenous plasmids before the 
injection.  Mice were bled 2 weeks post inoculation for immunoblot analysis with mouse 
sera against B. burgdorferi antigens to determine infectivity, as described (182, 183, 
238, 239).  Reisolation of B. burgdorferi from mouse skin, bladder and joint tissues was 
performed 3 weeks post injection to assess the ability of spirochetes to infect mice (182, 
183, 225, 237, 240).  Euthanized mouse tissues were placed in BSK-II growth medium 
and incubated for up to 35 days; the presence of spirochetes was determined by dark-
field microscopy. The ID50 was calculated as described below. 
Determination of Infectious dose 50 (ID50) and statistical analysis. The dose 
required to infect 50% of the mice was experimentally determined for wild-type, ΔcheD 
mutant and the cheDcom strains, as described (181, 183). The data from the 
ID50 infection experiment and the single dose infection experiment for each strain were 
combined for the estimations of the 50% infectious dose. Comparison between strain 
ID50 values was made using a generalized linear model with a probit link function and 
the log of Dose.  This method is also known as probit regression and in it we assume 
identical slopes in the response/log-dose relationship but different intercepts for each 
strain.  Graphically those assumptions manifest themselves as dose response curves 
with lateral shifts corresponding to the changes in intercept.  Additionally, an 
overdispersion parameter was fit in order to accommodate greater homogeneity in 
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infection rates that would otherwise be permitted by the model.  All calculations were 
carried out using JMP V12 Software (SAS Institute Inc, Cary, NC). A p≤0.05 between 
samples was considered significant.  
 Assessment of spirochete acquisition and transmissions using mouse-tick-
mouse infection assays. To assess if naïve Ixodes scapularis ticks are able to acquire 
B. burgdorferi from infected C3H/HeN mice, survive in the ticks, and then transmit from 
the ticks to the naïve mice, we performed mouse-tick-mouse cycle experiments (181-
183). Briefly, naïve mice were injected with in vitro-grown spirochetes to infect 100% 
mice (100 x ID50). Before performing any infection studies, spirochetes were verified by 
PCR to ensure that each clone retained all endogenous plasmids required for 
persistence infection in mouse and tick hosts (143, 159, 182, 183, 225). To verify the 
infection status, mice were bled 2 weeks post-inoculation and sera were tested using B. 
burgdorferi cell lysates by immunoblotting. Three weeks post-injection, naïve larval ticks 
were fed to repletion on separate spirochete infected mice (3 mice per bacterial strain; 
~200 larvae/mouse) for 5 to 7 days and collected once they dropped off the mice to 
determine acquisition of spirochetes from mice to ticks.  To determine percentage of 
spirochete-positive ticks for each B. burgdorferi clone, fed ticks were squashed 
individually to isolate genomic DNA followed by B. burgdorferi flaB-gene specific PCR, 
as described (181, 183, 230, 241). Seven days after drop-off, fed larvae was surface 
sterilized using 3% H2O2 followed by 70% ethanol, crushed individually in BSK-II 
medium, and plated in semi-solid BSK to determine viable spirochetes per tick (i.e., 
acquisition of spirochetes from infected mice to larval ticks) (143, 181, 225, 237, 240). In 
determining the total number of spirochetes per fed tick, 10 ticks were analyzed for each 
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strain and the results are expressed as a scatter plot with the mean. Statistical analysis 
was performed as described below. A second subset of fed larvae was allowed to molt. 
Two to three weeks after the molt, nymphal ticks were allowed to feed on naïve mice to 
determine transmission of spirochetes from infected nymphs to mice (143, 190). Naïve 
C3H/HeN mice were anesthetized and groups of nymphs were confined to capsules 
affixed to the shaved backs of the mice (3 mice per strain; 15 nymphs/mouse) (143, 
242, 243). The ticks were allowed to feed until repletion (3 to 5 days) and then collected 
from the capsules. At 7 days post-repletion, ticks were squashed individually, and 
spirochete burdens were determined as described above. Statistical analysis was 
performed as described below. Mice were euthanized 3 weeks post-repletion, and the 
transmission of the spirochetes was evaluated by reisolation. 
 Statistical analysis. The significance of the difference between the mean values 
of the groups was analyzed as follows. Unless otherwise stated, for all data, normality 
was checked using Shapiro-Wilk normality test. If the data passed normality, a multiple-
comparison analysis was performed by using a one-way analysis of variance (ANOVA) 
followed by a Tukey’s post hoc test. If the data did not pass normality, a multiple-
comparison analysis was performed by using a Kruskal-Wallis test, followed by Dunn 





Phosphatase activity of CheX is enhanced by CheD 
Amino acid sequence analysis of B. burgdorferi CheD indicates that it shares 
approximately 30% identity with B. subtilis and T. maritima CheD. Most importantly, the 
essential residues of B. subtilis and T. maritima CheD are also conserved in B. 
burgdorferi (not shown; see (206)).  In B. subtilis, CheD plays an important role in 
chemotaxis by modification of MCPs by deamidation of glutamine to glutamate residues 
or by enhancing chemotaxis CheC phosphatase activity to efficiently dephosphorylate 
the response regulator CheY, thereby regulating the levels of CheY-P (204-207). 
Because of the possession of the conserved residues, we predicted that B. burgdorferi 
CheD may exhibit similar functions as seen in other bacteria (204, 206, 220). B. 
burgdorferi genome lacks a homolog of CheC but possesses a functional phosphatase, 
CheX that efficiently dephosphorylate CheY3-P (222, 223). In order to test if B. 
burgdorferi CheD is able to stimulate the phosphatase activity, we first performed 
protein-protein interaction assays using affinity blotting as we supposed that CheD 
should bind to CheX in order to enhance the phosphatase activity. The affinity blotting 
data indicate that CheD interacts with CheX but not the chemotaxis response regulator 
CheY3 (Fig. 2.1). These observations suggest that CheD may be able to stimulate the 
phosphatase activity.  
To determine if CheD is able to enhance phosphatase activity, we performed 
phosphorylation-dephosphorylation assays using recombinant purified CheA, CheY3, 






































Figure 2.1. Affinity blot analysis indicate that CheD specifically interacts with 
CheX. (A) Purified Strep-CheD was incubated with (right) or without (left) His-CheX 
followed by immunoblotting with polyclonal anti-CheX. The band at an apparent 
molecular mass of 19 kDa (Strep-CheD) was observed in blots probed with His-
CheX. (B) Purified Strep-CheD was probed with (right) or without (left) His-CheY3 
followed by western blotting with polyclonal anti-CheY3. The bands at an apparent 




phosphorylated, as we have reported previously (Fig. 2.2.A, lane 2) (208, 221, 222). 
Moreover, incubation of CheY3-32P with CheX for 2.5 minutes resulted in 
dephosphorylation of CheY3-32P by CheX (Fig. 2.2.A, lane 3) (222). Importantly, when 
CheD was added in the CheA-CheY3-CheX reaction mixture for 2.5 minutes, the 
CheY3-32P dephosphorylation was enhanced (Fig. 2.2.A, lane 4) and the level of 
CheY3-32P was completely diminished within 5 minutes (Fig. 2.2.A, lane 8). CheD itself 
did not affect CheY3-32P dephosphorylation (Fig. 2.2.A, lanes 5 and 9). Moreover, the 
enhancement of CheX phosphatase activity was dependent on the CheD concentration 
(Fig. 2.2.B, lanes 4 to 8), indicating that CheD efficiently enhances CheX phosphatase 
activity. 
To determine if CheD is able to modify a B. burgdorferi chemoreceptor MCP 
protein, we performed deamidation assays using recombinant purified proteins, as 
described (206, 220). Even though we were able to detect deamidation with the positive 
control (Bacillus subtilis chemoreceptor) MCP-A, our multiple attempts with various 
assay conditions failed to deamidate any B. burgdorferi MCP.  Since we were unable to 
detect deamidation of a MCP by CheD, we performed CheD-MCP protein-protein 
interaction assays alternatively, reasoning that CheD must first bind to a MCP in order 
to deamidate it.  Using recombinant purified MCP and CheD proteins in an affinity 
blotting, we were able to determine CheD-MCP interactions. Specifically, we found that 
CheD interacts with MCP3 and MCP4, but not MCP5 (Fig. 2.3). 
Construction of cheD mutant and complemented strains 




















Figure 2.2. CheD enhances phosphatase activity of CheX. Phosphorylation-
dephosphorylation assays using purified recombinant CheA (A), CheY3 (Y), CheX 
(X), and CheD (D) proteins. (A) Twenty picomoles of CheA was autophosphorylated 
using 10 μCi of [γ-
32
P]ATP (lane 1). CheA-
32
P was then incubated separately with 
160 pmol of CheY3 for 5 min (lanes 2 and 6). Radio-labeled CheY3-
32
P was 
incubated with 0.15 pmol of CheX for 2.5 min or 5 min (lane 3 or 7, respectively). 
CheY3-
32
P and CheX reaction mixture was incubated with (lanes 4 land 8) or without 





P. (B) CheX phosphatase activity was efficiently enhanced by CheD. CheA 
was autophosphorylated as described above (lane 1). CheA-
32
P was then incubated 
with 160 pmol of CheY3 for 10 min (lane 2). Radio-labeled CheY3-
32
P was mixed 
with 0.15 pmol of CheX for 5 min without CheD (lane 3) or with 0.2 pmol (lane 4), 2 
pmol (lane 5), 5 pmol (lane 6), 10 pmol (lane 7), or 20 pmol of CheD (lane 8). 
CheY3-
32
P was also incubated with 20 pmol of CheD to confirm that CheD did not 





P or CheD. Lane numbers were shown at the bottom of each gel 
images. Relative intensities (PI “volumes”) of CheY3-
32
P are shown in the right 
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Figure 2.3. CheD specifically interacts with MCP3 and MCP4. Affinity blotting was 
performed as described above. Purified Strep-CheD was probed with MBP-MCP3, 
MBP-MCP4, or MBP-MCP5 followed by immunoblotting with monoclonal MBP 
antibodies (Thermo Scientific). The bands at an apparent molecular mass of 19 kDa 
(Strep-CheD; arrows) were always observed in blots probed with MCP3 and MCP4, 
but not MCP5. 
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cycle of B. burgdorferi, we inactivated the gene using a kanamycin resistance cassette 
(PflgB-aph1) in the low-passage virulent wild-type clone B31-A3 (Fig. 2.4) (165, 181-
183). PCR analysis of the kanamycin-resistant clones indicating that the PflgB-aph1 
cassette was inserted in the cheD gene (not shown), resulting in successful construction 
of the mutant. Furthermore, we confirmed by PCR that the cheD mutant retained all 
linear and circular endogenous plasmids seen in the parental wild-type cells (data not 
shown). 
The cheD mutant (ΔcheD) was complemented in cis by genomic integration to 
ensure that the phenotype of the mutant was solely attributed to the mutation and not 
due to a secondary mutation elsewhere in the genome (Fig. 2.4) (165, 183). 
Accordingly, the cheD gene and its native promoter (PcheD) was fused together and 
inserted within bb0445 and bb0446 in the suicide vector pXLFCheD (230, 231). The 
insertion of PcheD-cheD was downstream of both the bb0445 and bb0446, and less likely 
to affect their expression, as reported previously (183, 230, 231). To detect the 
expression of cheD in the wild-type, ΔcheD mutant, and complemented cheD (cheDcom) 
cells, we performed qRT-PCR using gene-specific primers. Real-time PCR detected the 
cheD transcripts in wild-type and cheDcom cells, but not in the cheD mutant cells (Fig. 
2.5). Moreover, the level of cheD transcripts synthesized in the cheDcom cells was 
approximately 84% of wild-type cells, indicating the restoration of cheD synthesis in the 
cheDcom cells (Fig. 2.5). 
In vitro motility and chemotaxis phenotype of the ΔcheD mutant cells 




















Figure 2.4. Schematic diagrams showing the construction of ΔcheD mutant 
and complemented strains. Inactivation of cheD using the P
flgB
-aph1 cassette. 
Wild-type B. burgdorferi with cheD polycistronic operon consisting of bb0605-
bb0606/cheD-bb0607 genes. The P
flgB
-aph1 cassette was inserted within the 
cheD gene using HindIII restriction digestion. The P
cheD
-cheD DNA was inserted 
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ΔcheD chromosome 




























































Figure 2.5. Expression of cheD was abolished in the mutant but was restored 
in the cheD
com
 cells as determined by qRT-PCR. The relative transcript levels of 
cheD was determined in the wild-type, ΔcheD and cheD
com
 cells which were then 
compared with the expression of B. burgdorferi enolase gene. The bars represent 
the mean ± standard deviation of the mean from three samples. A representative 
result from two independent studies is shown here. N.D., not detected. 
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chemotaxis behavior and compared those results with the wild-type or cheDcom cells. 
The cheX mutant was reported to exhibit a constant flexing swimming pattern whereas 
the wild-type cells run, flex/stop, and then reverse or change their swimming direction 
(222). Since we showed that CheD enhanced the phosphatase activity of CheX, we 
postulated that the cheD mutant cells might display an altered motility or chemotaxis 
phenotype. Dark-field microscopic analysis indicated that the motility patterns of the 
cheD mutant (run-flex/pause-reversal) and its flexing frequency during swimming were 
not noticeably different from the wild-type cells (9-12 flexes per minute; data not shown). 
However, the chemotaxis was found to be significantly reduced when compared to the 
wild-type (p=0.002) or the complemented cheDcom cells (p=0.007) (Fig. 2.6.A). In swarm 
plate assays, the average swarm diameters of the ΔcheD mutant were approximately 
18% smaller than those of the wild-type or cheDcom cells (Fig. 2.6.A). Swarm plate assay 
is a group event where millions of bacteria attempt to migrate out from the initial site of 
inoculation (in a semi-solid plate) as they chemotax and metabolize neighboring 
nutrients resulting in a swarm ring. However, results obtained from such an assay may 
not accurately determine the chemotactic ability of an individual spirochete. Accordingly, 
we plated 20-50 B. burgdorferi cells in a semi-solid plate (same plates used for the 
swarm plate assay) to determine the chemotactic ability of individual cells by measuring 
their colony (swarm) size. Prolonged incubation of those plates produced colony sizes 
that were significantly smaller than the wild-type (p=0.0001) or cheDcom cells (p=0.014). 
On average, the colony size of ΔcheD mutants was approximately 13% smaller than 
wild-type or cheDcom cells (Fig. 2.6.B). Together, our results indicate that cheD plays an 

























































Figure 2.6. ΔcheD mutant cells are deficient in chemotaxis. (A) Swarm plate 
assays indicate a defect in chemotaxis exhibited by the ΔcheD cells. Approximately 
1x10
6
 B. burgdorferi cells from the indicated strains were spotted into 0.35% soft 
agarose plates which were then incubated for 5 days. The swarm diameter of each 
clone was measured in millimeters. A non-chemotactic cheY3 mutant was used as a 
control (208). Bars represent the mean ± standard deviation of the mean from each 
clone (data from at least 3 plates per clone). Statistical analysis was performed by 
using ANOVA, as described in the Materials & Methods. P-values between samples 
are shown at the top. (B) ΔcheD mutants display reduced colony size compared to 
the wild-type or complemented strains. B. burgdorferi cells from the indicated strains 
were plated on 0.4% soft agarose plates. Individual colony’s swarm ability was 
determined four weeks after inoculation. The colony size of each clone was 
measured in millimeters.
 
 P-values were determined using ANOVA. Values are 
indicative of the mean ± standard deviation of the averages from at least 3 plates (20 
individual colonies) per strain. P-values between samples are shown at the top 
where p≤0.05 was considered as significant. 
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B. burgdorferi ΔcheD mutant cells can establish infection in C3H/HeN mice by 
needle inoculation but display reduced infectivity. 
While the role of CheD in motility and chemotaxis has been demonstrated in 
other bacteria, its role in pathogenesis has not been determined in any bacterium. In 
order to evaluate the infection potential of the mutant, groups of C3H/HeN mice were 
challenged with 10-fold increasing doses of wild-type, ΔcheD or the complemented 
cheDcom cells to determine the 50% infectious dose (ID50). Immediately before the 
injections, we confirmed by PCR that these strains retained their endogenous plasmids 
(data not shown) (143, 182, 183, 225). Two weeks post inoculation, the mice were bled 
and their sera were assessed for reactivity with B. burgdorferi antigen membrane 
protein A, also known as P39 (238, 239).  Furthermore, to confirm the serology results, 
mice were euthanized three weeks post-inoculation and spirochetes were reisolated 
from ear, bladder and joint tissues. Serology results indicated that cheD mutant cells 
were attenuated in establishing an infection in mice (not shown) and correlated well with 
reisolation of spirochetes from tissues examined (Table 2.2).  Whereas the cheDcom 
cells did not show a significant increase in the ID50 compared to the parental wild-type 
cells (p=0.3), the ID50 for the cheD mutant was approximately one logarithm higher than 
that of wild-type or cheDcom, indicating a significant attenuation in virulence (p=0.012 or 
p=0.0005, respectively) (Table 2.2). 
Ixodes scapularis ticks are able to acquire and transmit mutant B. burgdorferi. 
Because infection of and survival within the mammalian host represents only one 
aspect of the B. burgdorferi enzootic life cycle, a more comprehensive evaluation of the  
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Table 2.2. ΔcheD mutant cells are able to establish infection in C3H/HeN mice but 
the infectivity is considerably reduced* 
Strain Dose (CFU) 
No. of mice infected  





















*Mice were injected with the indicated B. burgdorferi clones and doses. Infectivity was 
determined by reisolation of B. burgdorferi from euthanized mouse tissues (ear skin, 
ankle joint, and urinary bladder). ID50 and statistical analyses were performed using 
Probit regression, as described in the Materials and Methods. The ΔcheD mutant 
spirochetes are significantly attenuated when compared to the ID50 of wild-type 
(p=0.0125) or the complemented B. burgdorferi (p=0.0005) where significance was 






activities of these mutants in the tick vector was justified. Naïve I. scapularis larvae were 
allowed to feed on infected mice in order to determine acquisition as well as viability of 
B. burgdorferi in larval ticks. Seven days after feeding on infected mice, a subset of 
larvae were squashed individually and purified genomic DNA in order to determine 
spirochete-positive ticks by PCR using B. burgdorferi flaB-gene specific primers. 
Another set of fed larvae were squashed individually for plating in semi-solid medium in 
order to determine viable spirochetes per tick. PCR data shown in Figure 2.7.A indicate 
that 100% of larvae that fed on wild-type, ΔcheD or cheDcom-infected mice were able to 
acquire the spirochetes (i.e., spirochete-positive). The burden of the mutant spirochetes 
per tick was not significantly lower than that of the wild-type (p=0.129) (Fig. 2.7.B). 
However, the burden of mutant B. burgdorferi was statistically less than the burden 
seen in larval ticks infected with the complemented cheDcom (p=0.007). 
In order to determine if the infected ticks are able to survive the molting and be 
able to transmit the mutant B. burgdorferi in naïve mice, a subset of fed larvae were 
allowed to molt. Two to three weeks after molting, infected nymphs were allowed to feed 
on naïve C3H/HeN mice (3 mice per strain, 15 nymphs per mouse). Seven days post-
repletion, nymphs were analyzed individually by plating on semi-solid plates, as above. 
Plating results indicate that the mutant spirochete’s burden in fed nymphs was 
considerably reduced compared to that of wild-type (p=0.013), however, the ΔcheD 
mutant’s load was not statistically different from the cheDcom infected nymphs (p=0.452) 
(Fig. 2.7.C) despite the fact that 100% of the nymphs were spirochete-positive by all 
clones (not shown, see Fig. 2.7.A).  


























Figure 2.7. Naïve ticks are able to acquire and transmit ΔcheD mutant 
spirochetes during mouse-tick-mouse infection studies. (A) Naïve ticks were 
allowed to feed on infected mice to determine acquisition of spirochetes. Ten larvae 
fed upon the wild-type, ΔcheD, or the complemented spirochete-infected mice were 
squashed individually to isolate DNA. Those DNA samples were then used to detect 
B. burgdorferi flaB by PCR. PCR data indicate that 100% of larval ticks were able to 
acquire the spirochetes from B. burgdorferi-infected mice (all groups). A tick’s DNA 
that we previously confirmed to be spirochete-positive was used as a positive control 
(+) and ddH2O was used as a negative control (-). (B) ΔcheD mutant spirochetes are 
able to survive in fed larvae. Viable ΔcheD spirochetes in fed larvae are reduced 
compared to the wild-type or complemented cells. P-values shown at the top were 
determined by using ANOVA, as described in the Materials & Methods. A p≤0.05 
between samples was considered significant.  (C) Mutant spirochetes are able to 
survive in fed nymphs, but the number of viable ΔcheD cells in fed nymphs are 
considerably less than the wild-type (p=0.013) but not statistically different from the 
complemented cheD
com
 cells (p=0.452). P-values were determined as described 
above where significance was defined as p≤0.05. A representative result from two 
independent studies with different batches of ticks is shown here. Bars represent the 
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the tick-fed animals were bled at two weeks post-feeding to perform serology followed 
by euthanization of mice to reisolate B. burgdorferi from ear, ankle joint, and urinary 
bladder tissues at 3 weeks post-repletion. Serology as well as bacterial outgrowth 
analyses indicate that the ΔcheD mutants are able to transmit and establish infection in 
all mice with no detectable deficiency (Fig. 2.8 and Table 2.3) even though we 
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Figure 2.8. Serology results of mice fed by the infected nymphs. Sera were 
collected from tick-bitten mice three weeks post-feeding, and immune responses 
were detected by Western blot. -, E. coli XL1 (negative control); +, E. coli expressing 
B. burgdorferi antigen P39; Bb, B. burgdorferi wild-type cell lysate. 
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Table 2.3. ΔcheD spirochete-infected nymphal ticks are able to transmit the 
organisms into naïve C3H/HeN mice* 
Strain 
No. of tissues positive 
/ No. examined 
No. of mice infected 
/ No. tested 
Wild-type 8/9 3/3 
ΔcheD 9/9 3/3 
cheDcom 8/9 3/3 
*Fifteen infected nymphs that are molted from larvae (from acquisition assay) were 
allowed to feed on one C3H/HeN mouse. Mice were euthanized 3 weeks post-repletion. 
Infectivity was determined by reisolation of B. burgdorferi from euthanized mouse 





 In this study, we systematically demonstrated that CheD specifically interacts 
with CheX and enhances phosphatase activity (Fig. 2.1 and 2.2). It is notable that 
CheC-type of phosphatases are monomers that possess two CheY-P 
dephosphorylation sites whereas the CheX-type of phosphatases are dimers containing 
only one dephosphorylation site (206, 222, 223, 244). Considering this distinction, this is 
the first report demonstrating the stimulation of CheX-type of phosphatases by CheD. 
CheD was reported to possess various functions in B. subtilis (204, 220, 245). While we 
were able to determine CheD-CheX relationship, our multiple attempts to deamidate B. 
burgdorferi MCPs by CheD were unsuccessful despite the fact that our positive control 
B. subtilis MCP deamidation was successful (204, 206), and we performed those 
assays using various conditions (data not shown). We, however, were able to show that 
CheD specifically interacts with MCP3 and MCP4, but not MCP5 (Fig. 2.3). It is possible 
that CheD binds to other MCPs, however, we chose to use these three MCPs because 
MCP3 and MCP5 are homologs of the major chemoreceptors Tar and Tsp of E. coli, 
respectively, and MCP4 possesses three CheD binding sites (Table 2.4). CheD binding 
to MCP3 and MCP4 suggest that either our deamidation assay conditions were not 
optimized or the CheD/MCP proteins purified from E. coli cells were non-
functional/inactive. 
 Because we found that CheD enhances CheX phosphatase activity and the cheX 
mutant constantly flexes (222), we supposed that the cheD mutant would also exhibit a 
motility phenotype. However, we failed to detect any noticeable difference in motility 
behavior exhibited by the ΔcheD cells. Even though the motility phenotype of the cheD  
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Table 2.4. Potential CheD modification substrate sites detected in B. burgdorferi 
chemoreceptors* 
Chemoreceptor 
Conserved sequence motif 
A/S  X  X  Q/E  Q/E  X  X  A/S 
B. subtilis MCP-A 
A  T  V  Q  Q  L  S  A 
G  E  L  Q  N  M  S  A 
B. subtilis MCP-C A  I  S  Q  E  S  A  A 
B. burgdorferi MCP1 S  R  S  Q  E  E  F  S 
B. burgdorferi MCP2 
S  L  L  E  Q  N  A  S 
A  S  V  E  Q  S  S  S 
B. burgdorferi MCP3 S  S  L  Q  E  Y  S  S 
B. burgdorferi MCP4 
S  A  L  Q  Q  A  S  A 
A  N  V  E  Q  I  A  S 
S  S  S  E  Q  L  S  S 
B. burgdorferi MCP5 S  T  L  E  Q  M  T  A 
*B. burgdorferi MCP chemoreceptor protein sequences were aligned with B. subtilis 
MCPs (George DG Molecular Microbiology 86(3):743-756 (2012)). Only the CheD 
modification amino acid residues from each MCP is shown here. Typically, CheD 









mutant was indistinguishable from the wild-type cells, we demonstrated that CheD is 
important for chemotaxis (Fig. 2.6). The chemotaxis effect is unrelated to the mutant’s 
growth rate in vitro since those cells grow normally in the BSK-II growth medium (not 
shown). Based on these findings, we propose that the enhancer function associated 
with the CheD is not likely to have a noticeable effect on CheX function in motility in 
vitro. 
Our mouse infection studies demonstrated that the mutant cells are able to 
establish infection in C3H/HeN mice, however, the mutant was significantly attenuated 
(Table 2.2). These results were not completely surprising given the fact that the non-
chemotactic cheX mutant cells are non-infectious in mice (M. A. Motaleb, unpublished 
data). In ΔcheD mutant cells, CheX, the only phosphatase in B. burgdorferi, is intact. 
Deletion of CheD likely had a minor effect on CheX proteins ability to dephosphorylate 
the CheY-P. Thus, the attenuation in mice we observed with the cheD mutant 
spirochetes is reasonable as the mutant did exhibit reduced chemotaxis phenotype (Fig. 
2.9). It is also plausible that the attenuation we found with the mutant spirochetes could 
be a result of the chemoreceptors not being modified/deamidated normally due to the 
deletion of cheD.  Moreover, we found that CheD is dispensable for acquisition or 
transmission of B. burgdorferi (Table 2.3 and Fig. 2.8) despite the fact that the viability 
of mutant spirochetes was reduced in ticks (both larvae and nymphs) and this reduced 
burden was detected consistently even though the P-values of wild-type vs. ΔcheD or 
cheDcom vs. ΔcheD were not always statistically significant (Fig. 2.7).  
Chemotaxis is found to be important for disease processes by many bacteria 













Figure 2.9. Role of chemotaxis in B. burgdorferi. In B. burgdorferi chemotaxis 
system, a histidine kinase CheA transfer its phosphate group to a response regulator 
CheY in order to phosphorylate it. The CheY-P then binds to the flagellar switch 
proteins to alter motility. CheX, the only phosphatase in B. burgdorferi, is able to 
dephosphorylate CheY-P (222, 223). However, the phosphatase activity is enhanced 
by CheD, resulting in fine-tuning the CheY-P levels in bacteria. Moreover, it appears 
that CheD plays an essential role in modifying some of the chemoreceptors to 
adapt/adjust sensing the environmental signals. Based on our observations to-date, 
we propose that chemotaxis is essential for transmission of B. burgdorferi and 
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• No dephosphorylation of CheY-P 
• Non-chemotactic bacteria 
• Non-infectious in mice 
• No transmission by tick 




















• Delayed dephosphorylation of CheY-P 
• Slightly reduced chemotaxis 
• Reduced infectivity in mice 
• Normal acquisition / transmission by tick 
• Reduced survivability in ticks 



















ΔcheD mutant suggest that either the in vitro assay condition does not reflect the in vivo 
host conditions (in vivo, the cheD mutant may be normal with respect to its chemotactic 
ability) or the chemotaxis defect we observed with the ΔcheD in vitro was not reduced 
enough to affect acquisition or transmission of spirochetes. However, our coherent 
observation of marginal reduced burden of cheD mutant spirochetes in ticks could be 
related to its activity in CheX as the cheX mutant spirochetes burden in ticks are also 
marginally reduced when compared to the wild-type (M. A. Motaleb, unpublished data). 
Moreover, we postulate that this phenotype is linked to less mutant spirochetes were 
acquired by the ticks while feeding or the viability defect is connected to the receptor 
MCP modification function. Further evaluation of MCP proteins role in B. burgdorferi or 
how CheD affects the receptors and their subsequent effect on virulence needs to be 
demonstrated. 
B. burgdorferi is a parasite that resides primarily in tick and rodents in the nature. 
Effective chemotaxis in these disparate habitats potentially explains the need for 
multiple chemotaxis systems in this organism. We propose that different adaptation 
systems (CheD or CheR1/CheR2-mediated) are likely employed to sense gradients of 
different scales and contours in these diverse environments. However, exactly how 
these chemotaxis systems contribute to the fitness of the Lyme disease spirochete is an 
open question. 
CHAPTER THREE: SPIROCHETES FLAGELLAR COLLAR 
PROTEIN FLBB HAS ASTOUNDING EFFECTS IN 
ORIENTATION OF PERIPLASMIC FLAGELLA, BACTERIAL 
SHAPE, MOTILITY, AND ASSEMBLY OF MOTORS IN 
BORRELIA BURGDORFERI 
ABSTRACT 
Borrelia burgdorferi, the causative agent of Lyme disease, is a highly motile 
spirochete, and motility, which is provided by its periplasmic flagella, is critical for every 
part of the spirochete’s enzootic life cycle. Unlike externally flagellated bacteria, 
spirochetes possess a unique periplasmic flagellar structure called the collar. This 
spirochete-specific novel component is linked to the flagellar basal body; however, 
nothing is known about the proteins encoding the collar or their function in any 
spirochete. To identify a collar protein and determine its function, we employed a 
comprehensive strategy that included genetic, biochemical, and microscopic analyses. 
We found that BB0286 (FlbB) is a novel flagellar motor protein, which is located around 
the flagellar basal body. Deletion of bb0286 has a profound effect on collar formation, 
assembly of other flagellar structures, morphology, and motility of the spirochete. 
Orientation of the flagella toward the cell body is critical for determination of wild-type 
spirochete’s wave-like morphology and motility. Here, we provide the first evidence that 





Lyme disease, which is caused by the spirochete, Borrelia burgdorferi, is the 
most prevalent vector-borne illness in the United States (1). In nature, survival of B. 
burgdorferi depends on migration by the bacteria to sites of colonization in Ixodes ticks 
and mammalian hosts (33, 34). The spirochete is a motile organism and motility is 
reported to be crucial for every part of the spirochete’s pathogenic life cycle, e.g., 
viability of B. burgdorferi in ticks, transmission from ticks to mice, persistent infection 
and dissemination in the mammalian host (143, 188, 190). 
The bacterial flagellar motor, such as those examined in Escherichia coli, is a 
highly efficient nano-machine, with a rotation frequency greater than 100 Hz, even 
though the diameter of the motor is only ca. 45 nm. The flagellum is a complex structure 
that is composed of three substructures whose assembly requires at least 25 different 
proteins. The basal body-motor portion of the flagellum is connected to the filament by 
the rod-hook assembly. When torque is generated by proton (or sodium in some 
organisms) flux, the flagellum stator rotates the filament propelling the organism to run 
or swim. The C-ring or switch complex, which is composed of FliG, FliM, and FliN 
proteins, is attached to the MS-ring basal body (FliF proteins) and stator (MotA-MotB). 
The C-ring determines whether a motor rotates clockwise (CW) or counter-clockwise 
(CCW) (247-250). 
Spirochetes are a group of motile bacteria that are distinct from other externally 
flagellated bacteria such as those seen in E. coli in many different aspects (138, 162, 
164). For example, B. burgdorferi is a long organism (10-20 µm) that possesses 7-11 
flagella inserted at each pole of the cell (up to 22 flagella per cell). Unlike E. coli, B. 
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burgdorferi flagella are located between the outer membrane and peptidoglycan layer 
i.e., in the periplasmic space (138, 188, 198, 251, 252). B. burgdorferi motility and 
chemotaxis genes are controlled by housekeeping σ70 promoters. This results in the 
flagella of this spirochete being assembled in a sequential manner. Moreover, the 
flagellar motors of spirochetes, specifically those of B. burgdorferi, are much larger than 
E. coli motors (~80 vs. ~45 nm) and thus require more gene products for their assembly 
(138, 163, 173). 
The periplasmic flagella originate near the cell poles and extend toward the other 
pole of the cell or toward the cell body. In motile cells, the periplasmic flagellar filaments 
form a ribbon-like structure that wraps around the cell body, resulting in a distinctive flat-
wave morphology (188, 190, 198, 251). It has been proposed that the spirochete’s 
flagella rotate asymmetrically during a “run” mode, i.e., flagella at one pole rotate CW 
whereas the flagella at the other end rotate CCW. When flagella at both poles rotate in 
the same direction, the spirochete flexes/tumbles (138, 210). While flagella in most 
other bacteria are involved in motility, periplasmic flagella in B. burgdorferi determine 
the cellular morphology as well as motility. For example, a mutant that lacks FlaB 
encoding the protein component of the periplasmic flagellar filaments produces a rod-
shaped cell in addition to being non-motile (143, 172). Due to their involvement in 
cellular morphology and the fact that these flagella rotate within the periplasmic space, it 
is not surprising that spirochetes possess extra or unique flagellar structures that offer 
flexibility or rigidity that is required to rotate their flagella within the periplasmic space. 
Recently, cryo-electron tomography (cryo-ET) of spirochete flagellar motors revealed 
unique features that are absent from all other bacterial motors studied to-date. One of 
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these structures is called the “collar” (Fig. 3.1) (162, 164, 253-255). The collar appears 
to be located adjacent to FliL. FliL homologs are found in several species of bacteria 
and its function is distinct in those organisms (165, 256-261). In B. burgdorferi, we found 
that periplasmic flagellar filaments were partially and abnormally tilted toward the cell 
pole in the ΔfliL mutant (165). 
Importantly, the collar is apparently integrated with the major components of the 
periplasmic flagella such as the MS-ring. Because of these connections and its central 
location in the motor, we hypothesize that the collar is critical for flagellar assembly as 
well as for providing proper rigidity or flexibility of flagella during rotation. However, 
nothing is known about the proteins encoding the unique collar structure or their 
function in any spirochete. In this communication, we show that mutations in bb0286 
(flbB) has a profound effect on collar formation, flagellar orientation, morphology, 
motility, and the assembly of FliL as well as the stator. Moreover, using green 
fluorescent protein (GFP) we determined the location of FlbB in the collar. A mechanism 























Figure 3.1. Unique collar structures are conserved in all spirochetes. (A) 
External flagellar motor of Escherichia coli; (B-D) periplasmic flagellar motors of the 
spirochetes, Leptospira interrogans, Treponema pallidum, and Borrelia burgdorferi. 
The distinctive collar structure is indicated using an arrow. Because of the dynamic 
nature of the E. coli stator, it was not visualized by cryo-ET (A). (E, F) Schematic 
models of the external flagellar motor of E. coli (E) and the periplasmic flagellar 
motor of B. burgdorferi (F). Periplasmic flagella are distinct from the external flagella, 
as they are enclosed within the outer membrane and their flagellar motors are 
considerably larger and more complex. However, the core architecture of the two 
flagellar types is comparable. Shared structures include the export apparatus, stator, 
the MS-ring, the C-ring, the rod connecting the hook with the MS-ring, hook, and 
filament (not shown) (164). Unique collar structure in the periplasmic flagellar 
apparatus is shown using an orange color. IM, inner membrane; OM, outer 




















MATERIALS AND METHODS 
Bacterial strains, plasmids, and growth conditions. The bacterial strains and 
plasmids used in this study are listed in Table 3.1. High-passage, avirulent B. 
burgdorferi strain B31-A was used as a wild-type clone throughout the study (224, 225). 
Construction of a flbB (bb0286) deletion mutation was achieved as described below. B. 
burgdorferi cells were cultured in liquid Barbour-Stoenner-Kelly (BSK-II) medium, and 
plating BSK was prepared using 0.4% agarose (143, 227). Cells were grown at 35°C in 
a 2.5% CO2 incubator as described previously (227). E. coli cells were grown at 30°C or 
37°C in Luria-Bertani (LB) broth or LB agar (229). Antibiotics, indicators, and inducers, 
when required, were included in the bacterial culture medium with the following 
concentrations: 100 μg/ml ampicillin, 50 μg/ml kanamycin, 100 μg/ml streptomycin, 40 
μg/ml gentamicin, 80 μg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 
0.5 mM isopropyl-β-D-thiogalactoside (IPTG). 
 Construction of the flbB-deletion mutant. Construction of the flbB-deletion 
plasmids, electroporation, and plating conditions were described previously (143, 182, 
183, 227). Briefly, the 5’- (1198 bp), and 3’-flaking (432 bp) DNA of flbB gene were 
amplified by PCR from chromosomal DNA of B. burgdorferi strain B31-A using primers 
FlbB.KO.P1F (GACGATTAGAACCTACTTTCG) and FlbB.KO.P1R 
(TAAAATTGCTTTTAACTATTATTCACTTTCATTCC), and FlbB.KO.P2F 
(CGATGAGTTTTTCTAATCATTGGAGTAGTGTG) and FlbB.KO.P2R 
(TTGGTCCTTAGAGTCATCT), respectively. Promoter-less kanamycin resistance 
cassette [Pl-kan, 846 bp] was similarly PCR amplified from PflgB-aph1 using primers 
FlbB.KO.KanF (GGAATGAAAGTGAATAATAGTTAAAAGCAATTTTA) and  
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Table 3.1. Bacterial strains and plasmids used in this study 
Strains or Plasmids Relevant characteristics* Reference or Source 
Borrelia burgdorferi   
B. burgdorferi B31-A B31 (ATCC 35210), the prototype 
strain of B. burgdorferi sensu 
stricto, originally isolated from a 
tick collected on Shelter Island, 




B. burgdorferi B31-A 
ΔflbB 
 
B31-A derived, ΔflbB, KanR This study 
B. burgdorferi B31-A 
GFP 




B. burgdorferi B31-A 
ΔflbB/flbB-GFP 





B. burgdorferi B31-A 
ΔflaB 
 
B31-A derived, ΔflaB, KanR Lab collection 
(172) 
B. burgdorferi B31-A 
ΔfliL 
 
B31-A derived, ΔfliL, StrpR Lab collection 
(165) 
   
Escherichia coli   
E. coli DH5α Transformation host for cloning 
vector, F- Φ80dlacZΔM15, 
Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17(rk-,mk+) phoA, 
supE44 thi-1 gyrA96 relA1 
 
Promega Inc. 
E. coli BTH101 Host for BACTH system. F-, cya-
99, araD139, galE15, galK16, 




   
Plasmids   
pGEM-T Easy Cloning vector for PCR product, 
ColE1 ori, AmpR 
 
Promega Inc. 
pBSV2G Shuttle vector, ColE1 ori, GentR 
 
(264) 




Table 3.1. Bacterial strains and plasmids used in this study (~continue) 
Strains or Plasmids Relevant characteristics* Reference or Source 
Plasmids   
pKT25 BACTH vector designated to 
express a given polypeptide 
fused in frame at its N-terminal 
end with T25 fragment (amino 




pUT18C BACTH vector designated to 
express a given polypeptide 
fused in frame at its N-terminal 
end with T18 fragment (amino 




pKT25-zip BACTH positive control vector, 
derivative of pKT25 in which the 
leucine zipper of GCN4 is 




pUT18C-zip BACTH positive control vector, 
derivative of pUT18C in which the 
leucine zipper of GCN4 is 




Teasy::flbB_KO flbB-Pl-aph1 in pGEM-T Easy for 





PflgB-flbB-gfp in pBSV2G for 
expression of FlbB-GFP, AmpR 
 
This study 
pKT25::fliL fliL orf in pKT25, KanR 
 
This study 
pKT25::flbB flbB orf in pKT25, KanR 
 
This study 
pKT25::motA motA orf in pKT25, KanR 
 
This study 
pKT25::motB motB orf in pKT25, KanR 
 
This study 
pUT18C::fliL fliL orf in pUT18C, AmpR 
 
This study 
pUT18C::flbB flbB orf in pUT18C, AmpR 
 
This study 




Table 3.1. Bacterial strains and plasmids used in this study (~continue) 
Strains or Plasmids Relevant characteristics* Reference or Source 
Plasmids   
pUT18C::motB motB orf in pUT18C, AmpR This study 
*KanR, kanamycin resistance; GentR, gentamicin resistance; StrpR, streptomycin 





















FlbB.KO.KanR (CACACTACTCCAATGATTAGAAAAACTCATCG) (182). These three 
pieces of DNA fragments were linked by overlapping PCR, yielding bb0285-Pl-kan-
bb0287 (flbB_KO_Pl-kan), then cloned into the pGEM-T Easy (Promega Inc.), yielding 
plasmid Teasy::flbB_KO_Pl-kan. Competent B31-A cells were electroporated with 
flbB_KO_Pl-kan PCR amplified linear DNA. The transformants were selected with 200 
μg/ml kanamycin. The kanamycin-resistant transformants were isolated and confirmed 
the replacement of flbB gene with the Pl-kan by PCR, and lack of FlbB protein 
expression was confirmed by immunoblotting as described below. 
Construction of a plasmid expressing FlbB-GFP. To construct a B. 
burgdorferi strain that expresses GFP coupled with FlbB, the flgB promoter (PflgB), and 
flbB gene were PCR amplified from chromosomal DNA of strain B31-A using primers 
PflgB-BamHI.F (GGATCCCGAGCTTCAAGGAAGATTTCC) and PflgB-flbB.R 
(ATAAAAAATTATTCACATGGAAACCTCCCTCATTTAAAA), and PflgB-flbB.F 
(TGAGGGAGGTTTCCATGTGAATAATTTTTTATCGTTC) and flbB-gfp.R 
(TCTTCTCCTTTACTCTCCAATGAACTAACAG), respectively (BamHI restriction site is  
underlined). gfp was PCR amplified from pMC2498 plasmid using primers flbB-gfp.R 
(CTGTTAGTTCATTGGAGAGTAAAGGAGAAGA) and gfp-HindIII.R 
(AAGCTTCTATTTGTATAGTTCATCCATGCCATG) (HindIII restriction site is 
underlined) (262, 263). These three pieces of DNA fragments were linked by 
overlapping PCR and cloned into the pGEM-T Easy, yielding plasmid Teasy::PflgB-flbB-
gfp. This and the B. burgdorferi shuttle vector pBSV2G were digested with BamHI and 
HindIII, and ligated to yield pBSV2G::PflgB-flbB-gfp (264). Approximately 50 μg of 
pBSV2G::PflgB-flbB-gfp plasmid DNA was electroporated into the ΔflbB mutant cells. 
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Transformants were selected with kanamycin and gentamicin. Resistant transformants 
were analyzed by PCR to confirm the presence of the pBSV2G::PflgB-flbB-gfp plasmids 
in the transformants (ΔflbB/flbB-GFP cells). Furthermore, the expression of GFP and 
FlbB proteins in the ΔflbB/flbB-GFP cells were confirmed by immunoblotting with B. 
burgdorferi FlbB-specific polyclonal and Anti-GFP monoclonal (Roche Life Science) 
antibodies, respectively. Anti-FlbB was raised in rabbits which immunized with purified 
recombinant His6-FlbB, as described (Alpha Diagnostic International) (165). 
SDS-PAGE and immunoblot analyses. Sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and immunoblotting with an enhanced 
chemiluminescent detection method (GE Health Inc.) were carried out as reported 
previously (143, 172). The concentration of protein in cell lysates was determined by a 
Bio-Rad protein assay kit. Unless otherwise noted, 10 μg of lysate protein was 
subjected to SDS-PAGE and immunoblotting using proper antibodies. 
Dark-field microscopy and measurement of colony size. Growing B. 
burgdorferi cells (2-4 x107 cells/ml) were imaged using a Zeiss Imager M1 dark-field 
microscope connected to a Zeiss AxioCam MRc digital camera to determine 
morphology. For measurement of B. burgdorferi colony swarm diameter, approximately 
20 to 50 cells were plated on semi-solid BSK-II medium containing 0.4% agarose. Four 
weeks after inoculation, we measured the diameter of 20 representative colonies from 
each clone (265). 
Confocal laser scanning microscopy. B. burgdorferi cells were examined with 
a confocal microscope (LSM 510; Carl Zeiss, Inc., Thornwood, NY, USA) using 488 nm 
Argon ion laser excitation and a 505-550 bandpass filter to collect GFP fluorescence 
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emission, with simultaneous collection of a transmitted light image using differential 
interference contrast (DIC) optics. Images were acquired and analyzed using Zen 2009 
software (Zeiss Inc.). 
 Cryo-electron tomography (cryo-ET) and subtomogram averaging. Frozen-
hydrated specimens were prepared as described previously (163, 190). Briefly, growing 
B. burgdorferi wild-type, ΔflbB mutant, and flbB-GFP cells were harvested at low 
1,500xg speed, and suspended in 40 μl phosphate buffered saline (PBS, pH 7.4) at a 
final concentration of ~2 x 109 cells/ml. Resuspended cells were mixed with 10 nm gold 
clusters, then 5 μl was deposited onto freshly glow-discharged holey carbon grids for 1 
min. Grids were blotted with filter paper to remove excess fluid, followed by rapid 
freezing in liquid ethane maintained at -180°C using a gravity-driven plunger apparatus 
(163, 266). The resulting frozen-hydrated specimens were imaged at -170°C using a 
Polara G2 electron microscope (FEI Company) equipped with a field emission gun and 
a K2 direct electron detector (Gatan). The microscope was operated at 300 kV with a 
magnification of x9,400, resulting in an effective pixel size of 4.6 Å . Using the FEI batch 
tomography program, low-dose single-axis tilt series were collected from each 
bacterium at a -6 μm defocus with a cumulative dose of ~60 e-/Å 2 distributed over 60 
images. Tilt angles were in the range of -60° and +60° with an angular increment of 2°. 
Tilt series were aligned and reconstructed using IMOD software and tomoauto (267, 
268). 
 In total, 285 and 190 reconstructions were generated from ΔflbB mutant and flbB-
GFP cells, respectively. A total of 1,742 motor sub-tomograms (256x256x256 voxels) 
were visually identified, then extracted from the reconstructions. The initial orientation of 
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each particle was estimated by the C-ring and the hook, thereby providing two of the 
three Euler angles. To accelerate image analysis, 4x4x4 binned sub-tomograms 
(64x64x64 voxels) were used for initial alignment. The original data was then used for 
the refinement and averaging as described previously (163, 266). 
3D visualization. Reconstructions of B. burgdorferi cells were visualized and 
segmented manually using IMOD (267). UCSF Chimera, a visualization system for 
exploratory research and analysis, was utilized for 3-D surface rendering of sub-
tomogram averages (269). 
Co-immunoprecipitation (co-IP). FlbB and FliL protein-protein interactions were 
determined using a Dynabeads®  Protein A Immunoprecipitation kit, according to the 
manufacture’s protocol (Novex Inc.). Briefly, 36 μg of rabbit polyclonal FlbB antibodies 
were diluted in 600 μl of PBS with 0.01% Tween 20, and then coupled the antibody with 
1.5 mg of Dynabeads. To prepare cell extracts, wild-type or ΔflbB mutant B. burgdorferi 
cells were harvested. Cell pellets were resuspended in PBS with 0.01% Tween 20 and 
then lysed by sonication. Sonicated cell extracts were centrifuged at 16,000 x g for 15 
min at 4°C to remove bacterial debris. Approximately 750 μg cell extracts were 
incubated with FlbB antibody-conjugated Dynabeads with gentle shaking for 10 min at 
room temperature, and washed with 1 ml of washing buffer for four times. 50 μl of SDS 
loading dye was added directly to the FlbB antibody-conjugated Dynabeads after the 
washes, and then heated for 10 minutes in boiling water bath. The boiled samples were 
subjected to SDS-PAGE and immunoblotting using B. burgdorferi FliL-specific 
antibodies (165). FlbB-MotB and FliL-MotB co-IP assays were similarly performed using 
B. burgdorferi FlbB, FliL, or MotB-specific polyclonal antisera (190). 
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 Bacterial two-hybrid system. Protein-protein interactions between FlbB and 
FliL were measured with the bacterial adenylate cyclase two hybrid system, according 
to the manufacture’s protocol (BACTH; Euromedex Inc.). Briefly, flbB and fliL genes 
were amplified by PCR from chromosomal DNA of B. burgdorferi strain B31-A using 
primers FlbB.BamHI.F (GGATCCCAATAATTTTTTATCG) and FlbB.KpnI.R 
(GGTACCCTCCAATGAACTAAC), and FliL.BamHI.F (GGATCCCCCTAATAAAGACG) 
and FliL.KpnI.R (GGTACCCATATCAAAAATATCAATT), respectively (restriction 
enzyme sites are shown in bold). These DNA fragments were cloned into the pUT18C 
and pKT25. Both pUT18C::flbB (or fliL) and pKT25::fliL (or flbB) were co-transformed 
into the BTH101 E. coli host cell. Transformants were grown on LB plates containing X-
gal, ampicillin, and kanamycin. Appearance of blue colored colonies in those plates is 
an indication of a positive protein-protein interaction. FliL-MotA, FliL-MotB, FlbB-MotA, 
and FlbB-MotB interactions were performed as described for FliL-FlbB. 
Statistical analysis. A paired Student’s t-test was used to determine statistical 





Identification of a protein encoding the collar structure 
Genomic analysis suggests that over 50 genes or 5–6% of the B. burgdorferi 
genome are potentially involved in motility and chemotaxis (138, 151). In order to 
identify proteins involved in the collar structure, we employed a strategy by subtracting 
common gene homologs that are present in other bacterial genomes especially those 
with externally flagellated bacteria whose motors have been determined by cryo-ET 
(162). To ensure that we did not overlook any gene that may share low homology but 
could encode a collar protein, we systematically mutated almost all genes annotated as 
“flagellar/motility-related” in the B. burgdorferi genome (138, 151) (our unpublished 
observation). Through these analyses, BB0286 (FlbB) was identified as a potential 
candidate for the collar structure. flbB is a spirochete-specific gene that is located within 
the flagellar flgB polycistronic operon, increasing the likelihood that this protein may 
encode for a flagellar gene (138, 270, 271). FlbB is a small protein (205 a.a.) that 
possess a transmembrane domain at its N-terminal end and shares no significant amino 
acid sequence identity with proteins from non-spirochetal bacteria (data not shown; see 
below). 
ΔflbB mutant cells are rod-shaped and non-motile 
We deleted the flbB gene by using a promoter-less kanamycin resistance 
cassette that results in nonpolar mutations (Fig. 3.2.A) (181-183). PCR analysis of the 
kanamycin-resistant B. burgdorferi clones confirmed the deletion of the flbB (data not 




















Figure 3.2. Construction of ΔflbB mutant and determination of polar effect on 
downstream genes expression. (A) Schematic diagrams of wild-type and ΔflbB 
mutant genomes. flaB gene (bb0147)  is separated from the targeted flbB gene 
(bb0286) by approximately 100 kb. Inactivation of flbB gene using the pl-aph1 
cassette is described elsewhere (182, 183). Wild-type B. burgdorferi with flgB 
polycistronic operon is shown (top). The pl-aph1 cassette replaced with flbB gene by 
allelic exchange (bottom) (182). The model lists only a few of the 26 genes in the 
flgB operon, and other genes are indicated by the multiple arrowheads. (B) 
Confirmation of flbB gene inactivation and determination of polar effect by Western 
blotting. Wild-type and ΔflbB mutant cell lysates were subjected to SDS-PAGE (left) 
and transferred to a PVDF transfer membrane for immunoblot analysis (right). 
Immunoblots were performed with B. burgdorferi FlbB, FlgE, MotB, FliL, or FlaB-
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was inhibited in the ΔflbB mutant cells; yet, expression of proteins encoded by genes 
downstream of flbB, i.e., flgE, motB, and fliL, were not altered in the mutant cells 
compared to the wild-type B. burgdorferi (Fig. 3.2.B). This suggests that the mutant 
phenotype is due solely to loss of flbB function (see below). Although the mutant did not 
exhibit a polar effect on downstream genes expression, we attempted to complement 
the ΔflbB mutant both in cis (genetic recombination) and in trans (using a shuttle 
vector). While multiple attempts to genetically complement the ΔflbB mutant have failed, 
we report our findings with the mutant as others have done in the past (165, 237, 272-
277). 
Dark-field microscopy and swarm plate assays were used to assess cell 
morphology and motility of ΔflbB cells (227, 265). These measurements indicated that 
the mutant cells are non-motile and display a rod-shaped morphology (Fig. 3.3), despite 
the synthesis of periplasmic flagella, FlaB, albeit at a reduced level compared to the 
wild-type (Fig. 3.2.B). Furthermore, swarm plate motility assays indicate that the mutant 
cells produced colony diameters that are significantly smaller than the wild-type cells 
(~1 mm vs. ~6 mm swarm produced by the wild-type; Fig. 3.3.B). The morphology and 
motility phenotypes of the ΔflbB mutant cells are similar to the non-motile, rod-shaped 
ΔflaB mutants that lack flagellar filaments (143, 172). Taken together, our results 
indicate that FlbB is important for morphology and motility of B. burgdorferi. 
ΔflbB mutant displays abnormal periplasmic flagellar orientation 
Previous studies showed that periplasmic flagella are crucial not only for motility 




















Figure 3.3. Morphology and motility phenotype of the ΔflbB mutant cells. (A) 
Dark-field microscopic images showing the distinct rod-shaped morphology of 
ΔflbB spirochetes (right) whereas the wild-type (WT) cells exhibit a flat-wave 
morphology (left). Growing B. burgdorferi cells were visualized using a dark-field 
microscope (40x) and images were captured using a digital camera. The mutant 
cells were also non-motile. (B) Swarm plate motility assays in 0.4% agarose. ΔflbB 
mutant cells display significantly reduced swarm diameter compared to wild-type 
cells. Individual colony’s swarm ability was measured four weeks after inoculation. 
The colony size of each clone is measured in millimeters.
 
Non-motile ΔflaB mutant 
was used as a control (172). Statistical analysis was performed by using Student’s t-





















































ΔflbB mutant cells synthesize periplasmic flagella but are rod-shaped, we investigated 
the basis of those defects using cryo-ET (Fig. 3.4). Our reconstructions of the native 
cellular structures shown in Figures 3.4.C and D indicate that the wild-type periplasmic 
flagella form ribbon-like structures that are oriented inwards toward the center of the 
cell. In contrast, the mutant’s periplasmic flagella are short and the flagellar ribbon is 
distorted. Most striking and opposite to wild-type, ΔflbB flagella are oriented abnormally 
toward the cell pole (compare Figs. 3.4.A-B with 3.4.C-D). In fact, the majority of 
periplasmic flagella (82% vs. 1-2% in the wild-type) are found to be abnormally oriented 
toward the cell pole in the mutant cells (Table 3.2). These results indicate that FlbB is 
essential for normal orientation of periplasmic flagella (toward the cell body). 
The collar structure is absent in the ΔflbB mutant cells 
We compared the motor structures in wild-type and the ΔflbB mutant cells by 
cryo-ET and found that the collar structure is absent from the mutant’s periplasmic 
flagella (Figs. 3.5.A, B). To reveal the motor structure in detail, we used subtomogram 
averaging to analyze approximately 1000 motor structures extracted from tomographic 
reconstructions. The averaged structure reveals major features of the flagellar motor, 
such as the export apparatus, the C-ring, the MS-ring, the rod, and the P-ring (Fig. 
3.5.C). These major features of the wild-type motor are also detected in the ΔflbB motor 
(Fig. 3.5.D). However, a large portion of densities surrounding the central rod and the P-
ring are absent in the ΔflbB motor (Fig. 3.5.D). Specifically, the ΔflbB motor lacks the 
collar structure detected in wild-type cells (compare Figs. 3.5.C, E with 3.5.D, F). 




















Figure 3.4. Periplasmic flagellar orientation in wild-type and ΔflbB mutant. (A) 
A representative tomographic slice of a ΔflbB cell showing that the periplasmic 
flagella are abnormally oriented toward the cell pole. (B) A cartoon model of the 
ΔflbB mutant shown in (A) clearly illustrated the abnormal tilting of the flagella. (C) A 
representative tomographic slice of a WT cell showing the periplasmic flagella that 
are extended toward the cell body but not the cell pole. (D) A cartoon model of the 







Table 3.2. ΔflbB mutant cells periplasmic flagella are oriented abnormally toward 
the cell pole 
Strain 
No. of cells 
analyzed 
No. of irregular 
periplasmic 
flagella* 






Wild-type 43 5 288 1.7 
ΔfliL 41 55 208 21 
ΔflbB 44 144 32 82 
*Irregular periplasmic flagella were tilted toward the cell pole. 
+Normal periplasmic flagella were tilted toward the cell body. ΔfliL mutant was used as a 






























Figure 3.5. Comparative analysis of in situ flagellar motors from wild-type and 
ΔflbB reveals the 3D collar structure for the first time. (A) A tomographic section 
from a WT cell shows the motors that are embedded in the cytoplasmic inner 
membrane (IM/CM). (B) A tomographic section from a ΔflbB cell shows a motor that 
is embedded in the cytoplasmic membrane. (C) The central section (left) and 
schematic diagram (right) of the WT flagellar motor. (D) The central section (left) and 
schematic diagram (right) of the ΔflbB flagellar motor. (E) The surface rendering of 
the 3D averaged WT and (F) ΔflbB motor structures are shown in side view. (G) The 
surface rendering of the 3D averaged WT motor structure is shown in tilted top view 
(90°). Compared to the motor structures from WT (C, E, G), the ΔflbB motor lacks 
the entire collar (blue), the stator (orange-red), and FliL (pink) structures. Noticeably, 
the collar is a large and complex structure comparing to FliL and the stator. OM, 
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unpublished), fliL (165), and the current ΔflbB strain, we were able to define the 3D 
structure of the collar and the stator (Figs. 3.5.E, G). The overall dimension of the collar 
is ~71 nm in diameter and ~24 nm in height. This unique structure consists of two major 
layers along the radial direction—for clarity, labeled here as the inner core domain and 
the outer turbine-like domain (Fig. 3.5.G). The inner domain of the intact collar appears 
to consist of 16 truss-like subassemblies joined together to form a chamber-like 
structure that surrounds the rod and the P-ring (Figs. 3.5.E, G). FliL is attached to each 
subassembly at the membrane region (Figs. 3.5.C, G). The outer domain—the sixteen 
extended “turbine blades”—is the most distinct feature appearing in the spirochetal 
flagellar motor. Sixteen stator units are inserted between two adjacent “turbine blades”, 
forming a stator ring that packs around the C-ring in the cytoplasm (Figs. 3.5.E, G). 
Furthermore, the stator (MotA-MotB) and FliL structures are also disappeared in the 
mutant even though MotB and FliL proteins are stably expressed at wild-type levels, 
suggesting that FlbB/collar is important for the assembly of those flagellar structures 
(compare Figs. 3.5.C, E with 3.5.D, F). Together, our cryo-ET data indicate that FlbB is 
essential for the formation of the collar structure and the assembly or stability of FliL and 
the stator. 
FlbB—FliL interactions 
As shown above, majority of ΔflbB mutant’s periplasmic flagella are abnormally 
tilted toward the cell pole. Interestingly, we observed a similar phenotype with our ΔfliL 
mutant cells (Table 3.2) (165). These results led us to predict that (a) FlbB and FliL 
proteins interact and direct the periplasmic flagella to orient toward the cell body but not 
the cell pole; (b) FlbB and FliL are located in close proximity to each other; and (c) 
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FlbB/collar is assembled before FliL and the stator because the FliL and stator 
structures are not assembled in the ΔflbB. To determine if FlbB interacts with FliL, we 
performed co-immunoprecipitation (co-IP) assays with wild-type and ΔflbB cell extracts. 
Our co-IP data indicate that FlbB specifically interacts with FliL (Fig. 3.6.A). The FlbB-
FliL binding is verified further by using an alternative bacterial two-hybrid assay 
(BACTH). Our two-hybrid assays also confirmed that FlbB interacts with FliL (Fig. 
3.6.B). These FliL-FlbB interaction results suggest that FlbB is located adjacent to the 
FliL, near the base of the collar structure (see below). 
Our motor structures show that the periplasmic domain of the stator is adjacent 
to the collar and that the stator structure is missing in the ΔflbB (Fig. 3.5). To test if there 
is any interaction between the stator and FlbB, and this interaction is important for the 
assembly of the stator, we performed co-IP and BACTH assays, as described above. 
Using these assays, we failed to detect any FlbB-MotA or FlbB-MotB interaction (data 
not shown), indicating that FlbB is not directly interacting with the stator and supporting 
our proposal that FlbB is just a small part of the collar that is located at its base (below). 
Localization of FlbB by GFP fusion 
To determine the location of FlbB in the periplasmic flagella, the gene encoding 
GFP was fused at the 3’-end of flbB (flbB-gfp) and then ligated such that flgB promoter 
drives the expression of flbB-gfp (PflgB-flbB-gfp) from the shuttle vector pBSV2G. The 
placement of gfp at the 3’-end of flbB is suitable for the expression of FlbB-GFP since 
the N-terminal region (7-29 amino acid residues) of FlbB is found to possess a 




















Figure 3.6. FlbB directly interact with FliL. (A) A co-IP assay showing the 
interaction between FlbB and FliL. FlbB-specific antibody conjugated with 
Dynabeads was incubated with wild-type or ΔflbB cell extracts. The proteins that 
were immunoprecipitated with the FlbB-antibody were separated using a gel, 
transferred to a PVDF-membrane, and subsequently, the membrane was blotted 
with anti-FliL (165). FliL proteins are co-precipitated with B. burgdorferi wild-type cell 
extracts (lane 1), but not with ΔflbB mutant extracts (lane 2). PBS buffer was used as 
a negative control (lane 3). To check for the non-specific protein binding on 
Dynabeads, we used empty Dynabeads (no Ab/antisera) in the co-IP with wild-type 
extracts (lane 4). Arrowheads indicate the positions of antibody heavy chain (~55 
kDa), light chain (~25 kDa), or FliL (~20 kDa). Lane numbers are shown at the 
bottom of the figure. (B) BACTH assays showing the interaction between FlbB and 
FliL, and self-interactions of FlbB-FlbB or FliL-FliL. E. coli cells harboring flbB or fliL 
gene in the vector pUT18C or pKT25 was transformed on a plate containing X-gal. 
Appearance of blue colored colonies indicate a positive protein-protein interaction. 
(-), negative control; (+), positive control; 1, pUT18C::flbB—pKT25::fliL co-
transformant; 2, pUT18C::fliL—pKT25::flbB co-transformant; 3, pUT18C::fliL—
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transmembrane inside outside 
# FlbB-GFP full-length: 442 a.a. (FlbB 1-205/GFP 206-442) 
# FlbB-GFP No. of predicted transmembrane (TM) helix: 1 
     FlbB-GFP TMHMM2.0 inside       1-6 a.a. 
     FlbB-GFP TMHMM2.0 TM helix   7-29 a.a. 
     FlbB-GFP TMHMM2.0 outside     30-442 a.a. 
Figure 3.7. Transmembrane domain prediction of FlbB-GFP fusion protein. 
FlbB possesses a transmembrane domain as predicted by TMHMM Server ver. 
2.0 software with default options. Predicted transmembrane region is indicated by 




Subsequent introduction of pBSV2G::PflgB-flbB-gfp into ΔflbB mutant cells 
resulted in expression of FlbB-GFP, as confirmed by immunoblotting using anti-GFP 
and anti-FlbB (not shown). Confocal microscopy shows the FlbB-GFP clusters at ~73% 
of the cell tips of the ΔflbB/pBSV2G::PflgB-flbB-gfp cells where motors are typically 
located (ΔflbB/flbB-GFP cells; Fig. 3.8, middle). As expected, this pattern (FlbB-GFP 
clusters) was not observed in the wild-type cells expressing only GFP using 
pBSV2G::PflgB-gfp plasmid (wild-type GFP; Fig. 3.8, left) or in the ΔflbB mutant negative 
control cells that does not express GFP (Fig. 3.8, right). 
To conclusively determine FlbB location, cryo-ET and subtomogram averaging 
were utilized to visualize the motor structure of the ΔflbB/flbB-GFP cells. Compared to 
the cellular density of ΔflbB motor, the ΔflbB/flbB-GFP motor shows extra densities near 
the basal body MS-ring structure as shown in Figure 3.9, suggesting the location of 
FlbB-GFP. Together, these data imply that FlbB proteins are located at the base of the 
collar and they are anchored to the cytoplasmic membrane to form the base for the 
























































Figure 3.8. Expression and location of FlbB-GFP in B. burgdorferi. Confocal 
microscopy showing the fluorescence (top), differential interference contrast (DIC; 
middle), and merged (bottom) micrographs of the wild-type GFP, ΔflbB/flbB-GFP, 
and ΔflbB cells at 64x. The white arrows indicate the location of FlbB-GFP in the 
ΔflbB/flbB-GFP cell tips (FlbB-GFP clusters were detected in approximately 73% 
cells tips). Even distribution of the GFP signal was observed throughout the wild-type 





















Figure 3.9. Location of FlbB-GFP as determined by cryo-ET. (A) The averaged 
3D motor structures of the ΔflbB/flbB-GFP cells, and (B) schematic diagram of the 
ΔflbB/flbB-GFP flagellar motor illustrating the location of FlbB at the base of the 
collar. (C) Three dimensional isosurface rendering of the ΔflbB/flbB-GFP flagellar 
motor is shown in side view. (D) Three dimensional isosurface rendering of the 
ΔflbB/flbB-GFP flagellar motor is shown in tilted (top) view. The yellow arrows 







Despite the fact that periplasmic flagellar motility is crucial for host colonization or 
disease production by the spirochetes including B. burgdorferi, there is still very limited 
knowledge about what genes encode for the spirochete-specific flagellar components. 
FlbB identified as a collar protein in this communication has profound effects in motility, 
morphology, orientation of periplasmic flagella, and assembly of motor proteins. The 
ΔflbB mutant cells are rod-shaped and non-motile despite the possession of periplasmic 
flagella (Figs. 3.2, 3.3, and 3.4), however, those flagella are inactive due to their missing 
stators (Figs. 3.5.D, F). Stator proteins use proton flux to produce torque in order for the 
flagella to rotate, which in turn enables the organism to translocate. Because the 
periplasmic flagella are oriented abnormally and their stators are missing, it was obvious 
that those B. burgdorferi mutant cells exhibited rod-shaped and non-motile phenotypes. 
However, the number of periplasmic flagella or level of flagellar filament FlaB protein is 
reduced in the mutant compared to the wild-type cells (Fig. 3.1.B). The flaB gene is not 
genetically linked with the targeted flbB or other genes in the flgB operon. However, we 
observed this reduced FlaB protein synthesis or fewer flagellar filaments not only in 
ΔflbB but also in other non-motile mutants such as ΔmotB (190). These observations 
suggest that the stator or collar-stator is important for the wild-type level of periplasmic 
flagellar filament synthesis in B. burgdorferi. 
One of the most remarkable findings here is the abnormal orientation of flagella 
in the ΔflbB mutant (Fig. 3.4 and Table 3.2). Normal orientation of the flagella toward 
the cell body and not the cell pole is critical in producing the wild-type spirochete’s 
wave-like morphology and smooth swimming (Figs. 3.3 and 3.4) (165). We have 
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previously reported that FliL is partially responsible for determination of flagellar 
orientation (165). As shown in Figure 3.4 and Table 3.2, 82% of the flagella in the ΔflbB 
are abnormally oriented. Thus, based on ΔflbB and ΔfliL flagellar orientation phenotypes 
as well as protein-protein interaction data shown in Figure 3.6, we propose that 
FlbB/collar—FliL structures enforce the periplasmic flagella to orient toward the cell 
body—an observation that has never been demonstrated in any spirochete. We, 
however, postulate that this irregular periplasmic flagellar phenotype associated with the 
mutant is a combined effect of collar-stator-FliL rather than just the FlbB/collar since the 
stator and FliL structures were diminished along with the collar (in the ΔflbB mutant). 
Moreover, it is important to note that the ΔflbB mutant was not complemented. Thus, the 
phenotypes observed with the mutant could be due to a secondary mutation elsewhere 
in the genome rather than just because of the deletion of flbB even though the mutant is 
non-polar (Fig. 3.2.B).  
The stator and FliL structures were not present in the mutants despite the 
synthesis of MotB and FliL proteins at the wild-type levels (Figs. 3.2 and 3.5.D, F), 
indicating that those structures were not assembled due to the lack of the collar 
structure. It is noteworthy to mention that the collar structure is intact in our ΔmotB (J. 
Liu and M. Motaleb-unpublished) or ΔfliL mutants (165). Furthermore, the stator is intact 
in the ΔfliL mutant—a very good indication that FliL and stator structures were 
diminished not because of a secondary alteration or polar effect (165). These results 
also suggest that the collar is assembled before FliL or the stator. Moreover, FliL and 
stator structures were not assembled in the ΔflbB likely because the collar provides the 
stability/foundation for those two motor structures similar to what was observed with the 
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flagellar filament proteins, FlaA and FlaB. FlaA and FlaB proteins interact and we found 
that unless the filament FlaB is synthesized and assembled, FlaA protein is not 
assembled in the ΔflaB (143, 172). 
In E. coli or Salmonella typhimurium, FliL was reported to interact with the stator 
(280). However, we could not detect any interactions between FliL-MotA, FliL-MotB, 
FlbB-MotA, or FlbB-MotB. These results suggest that FliL or FlbB may not interact with 
the stator directly. Alternatively, our BACTH vectors (pKT25 and pUT18C) could not 
express MotA or MotB properly or our co-IP reaction conditions were not optimized. 
However, in Rhodobacter sphaeroides, FliL is able to interact with itself but not with the 
MotB leading to the proposal that FliL may participate in coupling with the flagellar stator 
in an indirect manner (256). Moreover, in Vibrio alginolyticus, FliL was suggested to 
interact with the stator directly or indirectly (261). Subsequently, we propose that B. 
burgdorferi FliL (or FlbB/collar) interacts with the stator indirectly using a yet to be 
identified protein(s) which is important for the assembly of the stator. 
It is noteworthy that the full collar structure was not assembled in the ΔflbB cells 
expressing FlbB-GFP (Fig. 3.9), and morphology and motility phenotype were also not 
restored in those cells (not shown). This result is not surprising because in order for the 
collar structure or function to be restored in the ΔflbB, the FlbB-GFP protein’s 
stoichiometry should be the same as that of other collar proteins since most motor 
complexes maintain a ratio (such as the FliG:FliM:FliN protein copies in a switch 
complex are 34:34:100, and MotA:MotB ratio is 4:2 in a stator complex) (281-283). 
When GFP or mCherry was fused with flagellar motor MotA or MotB or their homologs, 
assembly and/or function was reported to be abolished in other bacteria (284, 285). 
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The collar is a colossal structural component of the periplasmic flagella. It is 
noticeably larger than the C-ring or stator (Fig. 3.5). Considering that the C-ring is 
composed of three proteins (FliG, FliM, and FliN), the collar is likely comprised of 
multiple proteins. FlbB is a small protein (205 amino acids) that is comparable to its 
binding partner FliL (178 amino acids) or MotB (260 amino acids). FliL appears to form 
a small and elongated structure right next to the edge of the collar (Figs. 3.5.C, G) 
(165). Therefore, we propose that FlbB is arranged in a small structure at the base of 
the collar by embedding in the cytoplasmic membrane using its transmembrane domain 
(Figs. 3.7 and 3.9). Other (unidentified) collar proteins are expected to assemble onto 
the FlbB base. As such, deletion of flbB had a dramatic effect on the entire collar, and 
thus, its associated structures are not assembled in the ΔflbB. 
Altogether, our data demonstrate that the collar is a highly complex structure that 
has profound impacts in B. burgdorferi. Importantly, we show for the first time that FlbB 
assembles around the flagellar basal body and plays critical roles in collar formation. 
Furthermore, we provided the first 3D structure of the collar and revealed its 
unprecedented complexity. Moreover, we show that FlbB and FliL are crucial for normal 
orientation of periplasmic flagella. 
 
CHAPTER FOUR: SUMMARY AND FUTURE DIRECTIONS 
 Borrelia burgdorferi is the causative agent of Lyme disease, which is the most 
prevalent vector-borne illness in the United States and Europe (1, 31). The disease is 
caused by at least three genospecies of bacteria in humans; B. afzelii, B. garinii, and B. 
burgdorferi sensu stricto (7). Among these, only B. burgdorfei sensu stricto causes 
Lyme disease in North America (1). This organism is an obligate parasite, and cycles 
between the Ixodes ticks and mammalian hosts in the nature. It is transmitted to 
mammalian hosts through the bite of a spirochete-infected tick (2, 3, 286). Completion 
of the enzootic cycle requires that B. burgdorferi not only traverse through dense and 
complex tissues within the tick to migrate from the midgut to the salivary glands, where 
they are transmitted to the next host during tick feeding (2, 143, 287), but also that B. 
burgdorferi, after being deposited into the dermis of a mammalian host, navigate the 
intracellular matrix, to the circulatory system of the host, and disseminate to distant 
organs, such as tibiotarsal joints, bladder, heart, and the nervous system, to produce 
various clinical manifestations (2, 143, 287, 288). The spirochete must complete these 
tasks all by simultaneously detecting what environment it is in, where it needs to go, and 
evading the immune systems of both hosts. Indeed, motility is shown to be absolutely 
required for migration of B. burgdorferi from skin to the distant tissues, for persistent 
infection in mice, transmission from the tick vector to the murine host, and optimal 
survival in the ticks (143, 190, 289). In addition, chemotaxis activities are important for 
successful completion of the enzootic life cycle of Lyme disease in order to allow the 
spirochetes to navigate from the mouse into the larval tick, during dissemination as well 
as from the nymphal tick into the mouse during transmission (189, 209). 
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Chapter 2 of this dissertation describes: 1) the biochemical roles of CheD in B. 
burgdorferi; 2) the role of cheD in B. burgdorferi motility and chemotaxis; and 3) defines 
the functions of cheD in the infectious life cycle of B. burgdorferi. 
Specifically, we have shown that CheD directly interacts with two of the five 
chemoreceptors, MCP3 and MCP4. However, CheD failed to deamidate those two 
chemoreceptors under various conditions tested. Since CheD is able to interact with 
those MCPs, we assume it can also deamidates MCP3-4 if the reaction conditions are 
optimized. Although not tested, we postulate that CheD is able to interact and 
deamidate the other MCPs (MCP1-2) since these two MCPs also possess the CheD 
substrate sites. These assays can further our understanding of the complex chemotaxis 
signalling pathways in B. burgdorferi.  Most interestingly, ligands for these receptor 
MCPs have not yet been identified. It is tempting to speculate that some of the 
receptors initiate chemotaxis signalling by engaging tick-specific ligands whereas others 
are activated by the mammalian host-specific nutrients. In support of this proposition, 
we found that Mother Nature has offered the spirochete two distinct chemotaxis 
signalling pathways (CheA1-CheY2 and CheA2-CheY3). It will be interesting to see if 
these predictions turn out to be true.  
We have shown experimental evidence that CheD enhances the CheX-type 
phosphatase. In other bacteria, such as B. subtilis, CheD enhances CheC phosphatase, 
and these CheC-type of phosphatases are monomers that possess two CheY-P 
dephosphorylation sites (205, 206), whereas CheX is a dimer containing only one 
dephosphorylation site (206, 222, 223, 244). To better understand how CheD stimulates 
CheX activity, X-ray co-crystal of CheD-CheX can be obtained to demonstrate the 
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differences between CheD-CheC and CheD-CheX interactions. This CheD-CheX 
structural analysis may provide some idea as to how CheD enhances CheX-type of 
phosphatases. 
Additionally and most importantly, we show for the first time that the cheD mutant 
displayed significantly attenuated infectivity in mice, and reduced viability in ticks. We 
also show the CheD does not play an important role in the acquisition and transmission 
of B. burgdorferi during the enzootic cycle; however, it is important to the survivability 
of B. burgdorferi within mammalian and tick hosts (Fig. 4.1). This in vivo phenotype is 
consistent with our hypothetical model (Fig. 2.9). We propose that in the cheD mutant, 
CheX is still intact but is less active due to the deletion of the enhancer CheD. 
Consequently, dephosphorylation of CheY-P by CheX still occurs but is delayed. This 
reduced infectivity of the cheD mutant makes sense in relation to the cheX mutant, 
which is deficient in chemotaxis and is unable to establish an infection in mice. 
Interestingly, the cheX mutant can survive normally in ticks (unpublished data) 
whereas the cheD mutant shows reduced viability. This reduced viability of the cheD 
mutant in tick host is still unclear. We postulate that this phenotype is likely linked to the 
MCP deamidation by CheD. This MCP modification by the CheD may involve in the B. 
burgodorferi survivability in tick hosts. 
It is noteworthy that the cheD mutant cells are able to establish an infection 
through transmission by ticks without any defect. However, the in vitro cultured cheD 
mutant displayed reduced virulence via needle inoculation. The reason for this 
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Figure 4.1. A model of CheD in the enzootic cycle of B. burgdorferi. In the 
enzootic cycle of B. burgdorferi, CheD is functional in the mammalian and tick hosts 
and important for infectivity in mouse and viability in ticks. However, it does not play 
an important role during aquisition from infected mouse to naïve larvae, nor during 
transmission from infected fed nymphs to mammals. 
Important 
for infectivity in mouse 
via needle inoculation 
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compared to the in vitro cultured spirochetes (290). 
Motility and chemotaxis work hand-in-hand as motility is governed by the 
chemotaxis system (138, 196, 200, 201, 203, 217). The Lyme disease spirochete is a 
motile organism, and motility, provided by its periplasmic flagella, is critical for every 
stage of the infectious life cycle of B. burgdorferi (143, 172, 188, 190). The periplasmic 
flagellar motors contain a novel structural component called the collar. Chapter 3 of this 
research project demonstrated 1) the identification of a collar protein; 2) determines the 
role of collar protein in motility, flagellar assembly, and periplasmic flagellar orientation; 
3) and identified additional collar proteins. 
Chapter 3 demonstrated the identification of a gene flbB that we found to be 
important for collar assembly for the first time. We have shown its role in motility, 
morphology, periplasmic flagellar orientation, and stability of other flagellar motors. In 
addition, we verified the location of FlbB in the flagellar motor. To ensure that FlbB is a 
spirochete-specific protein that is essential for the collar assembly, we will attempt to 
determine the role of FlbB in other representative spirochetes such as Treponema 
denticola or Leptospira biflexa as FlbB shares significant amino acid sequence identity 
in these other spirochetes [T. denticola FlbB (E-value 5e-20, 30% identity) and L. biflexa 
FlbB (2e-09, 25% identity)]. While not genetically tractable, we will attempt to 
complement a B. burgdorferi or T. denticola or L. biflexa flbB mutant with an intact wild-
type Treponema pallidum flbB gene. If we are able to complement a ΔflbB, it will show 
that the function of FlbB is also conserved in other spirochetes. 
As shown in chapter 3, the collar is a large structural complex and we, therefore,  
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proposed that the collar is comprised of multiple proteins. FlbB is a small protein (205 
amino acids) and using GFP, we have shown that it forms only a small structure at the 
base of the collar structure where FlbB is likely to be embedded in the membrane using 
its membrane-binding domain. Additional (unidentified) collar proteins are expected to 
assemble onto the base FlbB. Since we have inactivated all proteins annonated as 
flagellar/motility-related in the B. burgdorferi genome and found only FlbB to be involved 
in collar structure, we took advantage of a protein-protein interaction (PPI) map 
developed in another spirochete—T. pallidum—the causative agent of syphilis to 
identify additional proteins involved in collar assembly. 
Accordingly, we performed bioinformatics using the PPI map (291), and found 
several proteins including BB0236. BB0236 is shown to interact directly with the FlbB 
homolog in that map (Fig. 4.2). This BB0236 is annotated as a hypothetical protein and 
is away from any known motility/flagellar-related operons in B. burgdorferi. BB0236 
encodes a tetratricopeptide repeat (TPR) domain protein, which serves as a chaperone 
that helps stabilize multiprotein complexes in other bacteria (292, 293). Our preliminary 
data indicate that BB0236 interacts with FlbB in a co-immunoprecipitation assay. 
Moreover, mutant analyses indicate that BB0236 is crucial for motility, morphology, and 
the stability of other flagellar structures. Most importantly, our preliminary data indicate 
that BB0236 is a collar protein because the collar structure is absent in the bb0236 
mutant but is restored in the bb0236 complemented cells as determined by cryo-ET. 
Identification of BB0236 strongly suggests that the collar is a multiprotein complex 
because TPR proteins are shown to be involved in various multiprotein complexes in 


























BB0236 (TPR domain protein) 
; E-value 6e-80 / 27% identity 
Figure 4.2. Protein interaction network of Treponema pallidum. The protein-
protein interaction (PPI) map was produced between known motility proteins and 
proteins of unknown function by the yeast two-hybrid system (291). T. pallidum 
protein TP0567 shows 32% amino acid sequence identity with B. burgdorferi 
BB0286 (FlbB) and TP0567 is shown to interact with TP0421, TP0675, and TP0708. 




analyzing the potential candidates identified using the PPI map and determine their 
roles in motility and flagellar assembly. 
The long-term goal of this research project is to understand the mechanism of 
the spirochete’s distinctive motility and assembly of periplasmic flagella in B. 
burgdorferi, which can serve as a model to study the large macromolecular complexes 
in medically significant yet uncultivable spirochetal pathogens, such as T. pallidum, as 
well as many other significant spirochetes. Identification of virulence-associated flagellar 
structural proteins can lead to the development of a pharmacological agent to treat or 
prevent not only Lyme disease, but also other spirochete-borne diseases, such as 
syphilis and leptospirosis. 
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